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NOVELACYLTRANSERASES AND 
METHODS OF USING 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
0001. This application claims the benefit of priority under 
35 U.S.C. S 119(e) to U.S. Application No. 61/917,586 filed 
Dec. 18, 2013. The entirety of the prior application is incor 
porated by reference. 
FEDERALLY SPONSORED RESEARCHOR 
DEVELOPMENT 
0002 This invention was made with government support 
under DE-SC0001295, 2009-05988, and IOS 0701919 
awarded by the U.S. Department of Energy, the U.S. Depart 
ment of Agriculture, and the National Science Foundation, 
respectively. The government has certain rights in the inven 
tion. 
TECHNICAL FIELD 
0003. This disclosure generally relates to transgenic 
plants. 
BACKGROUND 
0004 Plants in the genus, Cuphea (Lythracea), accumu 
late high levels of medium chain fatty acids (MCFAs) in their 
seeds. MCFAs are useful in the chemical industry in the 
production of detergents, lubricants and biofuels. Camelina 
sativa is a member of the Brassicaceae family, and has been 
found to be a sustainable source of oil for petroleum products. 
A high proportion of polyunsaturated fatty acids in Camelina 
oil, however, has limited its usefulness in the biofuel industry. 
Therefore, methods of engineering the oil properties in Cam 
elina or other oil-producing organisms are desirable. 
SUMMARY 
0005. In one aspect, a method of producing triacylglycer 
ols (TAGs) comprising medium-chain fatty acids (MCFAs) in 
an organism is provided. Such a method typically includes 
introducing a transgene into the organism, wherein the trans 
gene comprises at least one nucleic acid sequence encoding 
an acyltransferase, wherein the at least one acyltransferase 
exhibits a substrate specificity for saturated fatty acids, 
thereby producing TAGs comprising MCFAS in the organism. 
0006. In some embodiments, at least 20% (at least 40%, at 
least 50%, etc., etc.) of the TAGs comprising MCFAs have a 
C8:0 or a C10:0 at sn-2 position. In some embodiments, the 
saturated fatty acids are selected from the group consisting of 
C8:0 and C10:0. 
0007. In some embodiments, the at least one acyltrans 
ferase is a lysophosphatidic acid acyltransferase (LPAT) or a 
diacylglycerol acyltransferase (DGAT). In some embodi 
ments, the at least one acyltransferase is a lysophosphatidic 
acid acyltransferase (LPAT) and a diacylglycerol acyltrans 
ferase (DGAT). In some embodiments, the nucleic acid 
sequence encoding the LPAT is selected from the group con 
sisting of a sequence having at least 95% sequence identity to 
SEQID NO:1 and a sequence having at least 95% sequence 
identity to SEQID NO:3. In some embodiments, the nucleic 
acid sequence encoding the DGAT is selected from the group 
consisting of a sequence having at least 95% sequence iden 
tity to SEQ ID NO:7 and a sequence having at least 95% 
Aug. 18, 2016 
sequence identity to SEQ ID NO:9. In some embodiments, 
the nucleic acid sequence encoding the at least one acyltrans 
ferase is selected from the group consisting of a nucleic acid 
sequence having at least 95% sequence identity to SEQ ID 
NO:1, a nucleic acid sequence having at least 95% sequence 
identity to SEQID NO:3, a nucleic acid sequence having at 
least 95% sequence identity to SEQID NO:7, and a nucleic 
acid sequence having at least 95% sequence identity to SEQ 
ID NO:9. 
0008. In some embodiments, the organism further com 
prises a nucleic acid sequence encoding a medium-chain fatty 
acid (MCFA)-specific thioesterase FatB. In some embodi 
ments, the nucleic acid sequence encoding the MCFA-spe 
cific thioesterase FatB is selected from the group consisting of 
a nucleic acid sequence having at least 95% sequence identity 
to SEQ ID NO:11, a nucleic acid sequence having at least 
95% sequence identity to SEQID NO:13, and a nucleic acid 
sequence having at least 95% sequence identity to SEQ ID 
NO:15. 
0009. In some embodiments, the organism is selected 
from the group consisting of a plant and a microbe. In some 
embodiments, the plant is Camelina sativa. 
0010. In some embodiments, the transgene comprises a 
promoter. In some embodiments, the promoter is a seed 
specific promoter. In some embodiments, the at least one 
nucleic acid sequence encoding an acyltransferase is oper 
ably linked to a seed-specific promoter. In some embodi 
ments, the medium-chain fatty acids are produced in the seed. 
0011. In some embodiments, the introducing step is per 
formed using Agrobacterium transformation, particle bom 
bardment, or electroporation of protoplasts. 
0012. In another aspect, a method of producing triacylg 
lycerols (TAGs) comprising medium-chain fatty acids (MC 
FAs) is provided. Such a method typically includes providing 
an organism comprising a transgene, wherein the transgene 
comprises at least one nucleic acid sequence encoding an 
acyltransferase, wherein the at least one acyltransferase 
exhibits a Substrate specificity for Saturated fatty acids; grow 
ing the organism under appropriate conditions; and obtaining 
TAGs comprising MCGAS from the organism. In some 
embodiments, the TAGs are used in biofuel, jet fuel, deter 
gents, and chemical feedstocks. 
0013. In still another aspect, a method of increasing the 
amount of triacylglycerols (TAGs) comprising medium 
chain fatty acids (MCFAs) in the seed oil of a plant is pro 
vided. Such a method typically includes providing a plant 
comprising a nucleic acid encoding a FatB polypeptide; intro 
ducing a heterologous nucleic acid molecule into the plant 
comprising at least one nucleic acid sequence encoding an 
acyltransferase, wherein the at least one acyltransferase 
exhibits a substrate specificity for saturated fatty acids, 
thereby increasing the amount of TAGs comprising MCFAs 
in the seed oil of the plant without significantly changing the 
total oil content in the seed. 
0014. Unless otherwise defined, all technical and scien 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
methods and compositions of matter belong. Although meth 
ods and materials similar or equivalent to those described 
herein can be used in the practice or testing of the methods 
and compositions of matter, Suitable methods and materials 
are described below. In addition, the materials, methods, and 
examples are illustrative only and not intended to be limiting. 
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All publications, patent applications, patents, and other ref 
erences mentioned herein are incorporated by reference in 
their entirety. 
DESCRIPTION OF DRAWINGS 
Part A 
0015 FIG. 1 shows the phylogenic relationship in 
deduced amino acid sequences of LPATs. Amino acid 
sequences of 6 LPATs from Cuphea pulcherrima (black tri 
angle) and 1 LPAT from Cuphea viscosissima (gray triangle) 
were aligned with putative orthologs of higher plants, which 
were obtained from the protein database of National Center 
for Biotechnology Information (NCBI). The phylogenic tree 
was built with the MEGA6 software, using the minimum 
evolution method with 1000 number of bootstrap replication. 
0016 FIG. 2 are the results of RT-PCR analysis showing 
spatial expression of Cuphea LPAT genes in diverse tissues. 
The Cuphea eIF4 and actin were used as internal controls. 
0017 FIG. 3 are photographs showing the subcellular 
localization of Cuphea LPATs. Single plane image of tobacco 
epidermal cells was obtained from confocal laser scanning 
microscopy. Left panels are YFP signals of Cuphea LPATs, 
middle panels are ER markers (A, C and D) and auto fluores 
cence of chloroplasts (B), and right panels are merged 
images. Bars=10 um. (A) CpulPATB; (B) CpulPAT1: (C) 
CpuLPAT2a: (D) CvLPAT2. 
0018 FIG. 4 is data showing the complementation test of 
Cuphea LPATs in mutated E. coli. The new Cuphea LPATs 
were transformed into the E. coli JC201 strain, a mutant strain 
that will not grow at non-permissive temperatures without a 
functional LPAT. 
0019 FIG. 5A is a graph showing the fatty acid composi 
tion of lipids (Mol% of TAG). 
0020 FIG. 5B is a graph showing the fatty acid composi 
tion of the sn-2 position of seed oil TAG. 
0021 FIG. 5C is a graph showing the total amount of 
FAME (ug)/weight (mg). 
0022 FIG.5D is a graph showing the fatty acid composi 
tion of lipids (Mol% of TAG). 
0023 FIG. 5E is a graph showing the fatty acid composi 
tion of the sn-2 position of seed oil TAG. 
0024 FIG. 5F is a graph showing the total amount of 
FAME (ug)/weight (mg). 
0025 FIG. 6 shows data demonstrating C14:0-containing 
TAG species detected by Neutral Loss ESI-MS/MS. Electro 
spray mass spectroscopy of TAG isolated from wild type (A) 
and 14:0 specific CpFatB2 (B) with CpuLPATB (C), CnL 
PATB (D), and CvLPAT2 (E). CN indicates the carbon num 
ber of TAG. 
0026 FIG. 7 provides the amino acid alignment of Cpull 
PATB homologs and information regarding the predicted 
transmembrane segments. (A) Amino acid alignment using 
the CLUSTAWL algorithm was generated using LPLAT-AG 
PAT-like domains of LPATB and LPAT1 homologs. Gray 
dotted boxes indicate acyltransferase motifs. Circles and 
black triangles are catalytic amino acids and binding site in 
acyltransferase motifs, respectively. (B) Predicted transmem 
brane region of CpulPATB by different programs; SOSUI, 
PSORTII, HMMTOP, and TMHMM server 2.0. The numbers 
indicate the amino acid residue of CpulPATB. (C) A sche 
matic showing topological transmembrane and acyltransferse 
motifs of CpuLPATB. 
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0027 FIG. 8 provides the amino acid alignment of CVL 
PAT2 homologs and information regarding the predicted 
transmembrane segments. (A) Amino acid alignment using 
the CLUSTAWL algorithm was generated using LPLAT-AG 
PAT-like domains of LPAT2 and LPAT3 homologs. Gray 
dotted boxes indicate acyltransferase motifs. Circles and 
black triangles are catalytic amino acids and binding site in 
acyltransferase motifs, respectively. (B) Predicted transmem 
brane region of CvLPAT2 by different programs; SOSUI, 
PSORTII, HMMTOP, and TMHMM server 2.0. The numbers 
are indicated the amino acid residue of CpulPATB. (C) A 
schematic showing the topological transmembrane and acyl 
transferase motifs of CvLPAT2. 
0028 FIG. 9 are graphs showing LPAT activity expressed 
in Agro-infiltrated tobacco leaf. 
(0029 FIG. 10 is data showing the C10:0-containing TAG 
species detected by Neutral Loss ESI-MS/MS. Electrospray 
mass spectroscopy of TAG isolated from wild type (A) and 
14:0 specific ChFatB2 (B) with CnLPATB (C) and CvLPAT2 
(D). CN indicates the carbon number of TAG. *: contains 
10/10/18:1, S: contains 10/10/20:1. 
Part B 
0030 FIG. 11 is an unrooted phylogram of C. pulcherrima 
DGAT1 (Cp)GAT1) and other hypothetical and functionally 
characterized DGATs. The alignment was generated by the 
CLUSTALW program and the unrooted phylogram was con 
structed by the neighbor-joining method in MEGA4 software 
(Tamura et al., 2007, Mol. Biol. Evol., 24:1596-9). 
0031 FIG. 12 is an alignment of deduced amino acid 
sequence of Cpl DGAT1 with some of its orthologs. 
0032 FIG. 13 is data showing CplDGAT1, CpDGAT2 A, 
CpGAT2 B and Cpl DGAT2 C expression analysis in C. 
pulcherrima tissues by SQRT-PCR of cDNA from total RNA. 
PCR products were obtained with gene specific primers for 
CpDGAT1, CplDGAT2 A, CpDGAT2 B or CpDGAT2 C. 
0033 FIG. 14 is a graph showing the short and medium 
chain fatty acid profile of CvFATb1+CpDGAT1 (T2) lines. 
0034 FIG. 15 is a graph showing the short and medium 
chain fatty acid profile in CvFatB1+CvLPAT2+CpDGAT1 
(T2) lines. 
0035 FIG. 16 is a graph showing the fatty acid profile of 
TAG from transgenic Camelina plants 
0036 FIG. 17 is a graph showing the fatty acid profile of 
MAG species separated following the digestion of TAG from 
mature seeds of wild type and transgenic Camelina CvFatB1, 
CvFatB1+CvLPAT2, CvFatB1+CplDGAT1, CvFatB1+CvL 
PAT2+Cpl DGAT1 lines and C. pulcherrima and C. viscosis 
SiC. 
0037 FIG. 18A is a graph showing the fatty acid profile in 
developing seeds from wild type and transgenic Camelina 
lines expressing CvFatB1, CvFatB1+CpGAT1, or 
CvFatB1+CvLPAT2+CpDGAT1 at 10 DAF (days after flow 
ering). At ten DAF, developing seeds contain very low 
amounts of 10:0 (-2.5 mol%); the main fatty acids were 16:0 
(-14 mol%), 18:1 (20 mol%), 18:2 (40-44 mol%), and 18:3 
(18-20 mol%). The percent share of each fatty acid (16:0 
through 20:1) in TFA in transgenic lines was similar to that of 
wild type Camelina plants. 
0038 FIG. 18B is a graph showing the fatty acid profile in 
developing seeds from wild type and transgenic Camelina 
lines expressing CvFatB1, CvFatB1+CpGAT1, or 
CvFatB1+CvLPAT2+CplDGAT1 at 17 DAF. 17 DAF seeds 
contain more medium-chain fatty acids (8:0 (4 mol%), 10:0 
US 2016/0237448 A1 
(up to 24 mol %), 12:0 (2.5-4 mol %), 14:0 (3 mol%)) and 
higher amounts of 16:0 (13 mol %) in transgenic lines. In 
CvFatB1+CvLpat2+CpDGAT1, the amount of 18:1 
decreases, while 18:2, 18:3 and 20:1 are present in amounts of 
15 mol %, 16 mol % and 6 mol %, respectively, as compared 
to 21.4 mol %, 30 mol % and 12.7 mol % in wild type 
Camelina plants. 
0039 FIG. 18C is a graph showing the fatty acid profile in 
developing seeds from wild type and transgenic Camelina 
lines expressing CvFatB1, CvFatB1+CpGAT1, or 
CvFatB1+CvLPAT2+CpDGAT1 at 22 DAF. 22 DAF seeds 
produce more medium chain fatty acids (5 mol% 8:0, 30 mol 
% 10:0, 7 mol % (12:0-14:0)). The amounts of 16:0, 18:0, 
18:1, 18:2, 18:3 and 20:1 in CvFatB1+CvLPAT2+CplDGAT1 
line are 12 mol %, 8 mol %, 12 mol %, 16 mol %, and 5 mol 
% as compared to 8 mol%. 13 mol%. 20 mol%. 41 mol %, 
and 10 mol % in seeds of wild type plants. Thus, the total 
share of 8:0 to 16:0 fatty acids in this line reaches 54 mol % 
of TFA as compared to 39 mol % in CvFatB1 line, 43% in 
CvFatB1+CpGAT1 line and just 8 mol % in wild type. 
0040 FIG. 18D is a graph showing the fatty acid profile in 
developing seeds from wild type and transgenic Camelina 
lines expressing CvFatB1, CvFatB1+CpGAT1, or 
CvFatB1+CvLPAT2+CplDGAT1 at 30 DAF. In 30 DAF seeds 
from CvEatB1 line, there is 33.6 mol% of 8:0-16:0, 22.4 mol 
% 18:1, 13.7 mol % 18:2, 16.0 mol % 18:3 and 6.6 mol % 
20:1. CvFatB1+Cpl DGAT1 transgenic lines accumulate more 
10:0, and 8:0-16:0 total fatty acid amount is 37 mol % while 
amounts of 18:1, 18:2, 18:3 and 20:1 are similar to what is 
found in seeds from CVFatB1 line. In CvPatE31+CvLPAT2+ 
CpGAT1 lines, the average share of 8:0-16:0 fatty acids is 
43 mol % of TFA, 18.5 mol % being 10:0 and 13.2 mol % 
18:1, 12.8 mol%. 18:2, 18.3 mol%. 18:3, 6.3 mol%. 20:1. 
0041 FIG. 19 is a graph showing fatty acid profile of TAG 
from N. benthamiana leaves infiltrated with CvPatB1, 
CvFatB1+CpDGAT1, CvFatB1+AthlDGAT1. 
0042 FIG. 20 is a graph showing DGAT activity in crude 
extracts of developing seeds from Wt and transgenic Cam 
elina lines. Values are meant-SD (n=3). Results are for assays 
using 1-14C10:0-CoA, and diacylglycerol (DAG) species: 
10:0/10:0 (1,2-didecanoyl-sn-glycerol) or 18:1/18:1 (1.2- 
dioleoyl-sn-glycerol). 
0043 FIG. 21 is a graph showing the seed weight of 
mature seeds from Wt and transgenic Camelina. 
0044 FIG. 22 is a graph showing the germination effi 
ciency of transgenic Camelina seeds. 
004.5 FIG. 23 is data showing 10:0/10:0 DAG containing 
TAG species detected by Precursor 383.3 m/z ESI-MS/MS 
SCaS. 
0046 FIG. 24 are graphs showing fatty acid profiles of a 
Camelina transgenic line. 
DETAILED DESCRIPTION 
0047. This disclosure is based on the discovery of novel 
nucleic acids encoding acyltransferase polypeptides. Such 
nucleic acids, SEQID NOs: 1, 3, 5, 7, or 9, and the polypep 
tides encoded thereby, SEQ ID NOS: 2, 4, 6, 8, or 10, are 
described and characterized herein. Based on this discovery, 
Such nucleic acid sequences can be used to produce particular 
and unique medium-chain fatty acids (MCFAS). 
0048. As described herein, lysophosphatidic acid acyl 
transferase (LPAT) and diacylglycerol acyltransferase 
(DGAT) catalyze sequential reactions in the Kennedy path 
way that produce triacylglycerols (TAG) in seeds and other 
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plant tissues and organs. Triacylglycerols are the principal 
component of vegetable oils, which are used in a variety of 
edible applications (e.g., baking, frying) as well as non-food 
applications, such as biofuels, lubricants, and Surfactants. 
LPAT uses fatty acids in the form of fatty acyl-Coenzyme A 
(CoA) as substrates for esterification to the sn-2 position of 
lysophosphatidic acid (LPA) to form phosphatidic acid (PA). 
Following dephosphorylation of PA, the resulting diacylglyc 
erol (DAG) serves as a substrate for addition of a fatty acid in 
the form of fatty acyl-CoA to its sn-3 position to generate 
triacylglycerol, via the activity of DGAT. LPAT activity in 
seeds of the typical oilseed crops, such as canola (Brassica 
napus), Camelina (Camelina sativa), and soybean (Glycine 
max) have strong specificity for unsaturated C18 fatty acid 
acyl-CoA substrates such as oleoyl (18:1)-, linoleoyl (18:2)- 
and linolenoyl (18:3)-CoA, but little or no activity with satu 
rated fatty acyl-CoA substrates (Sun et al., 1988, Plant 
Physiol. 88, 56-60; Oo et al., 1989, Plant Physiol. 91, 1288 
1295). This activity arises predominantly from LPATs of the 
LPAT2 class, but also with contributions from LPATs of the 
bacterial-type LPATB class Arroyo-Caro, J. M., Chileh, T., 
Kazachkov, M., Zou, J., Alonso, D. L., Garcia-Maroto, F. 
(2013) Plant Sci. 199-200:29-40. The strict substrate speci 
ficity of oilseed LPATs for unsaturated fatty acyl-CoA sub 
strates represents a major bottleneck for metabolic engineer 
ing of oilseeds to produce TAG with high levels of saturated 
medium-chain fatty acids with C6-C14 chain-lengths for 
applications such as biofuels, including bio-based Jet fuel A. 
These metabolic engineering strategies typically involve 
expression of divergent forms of the FatB acyl-ACP 
thioesterase that are able to produce medium-chainfatty acids 
of differing chain-lengths. An LPAT from coconut of the 
LPATB class has been previously shown to be effective at 
esterifying lauroyl (12:0)-CoA to the sn-2 position of LPA to 
produce lauric acid-rich oils when co-expressed with a 12:0- 
acyl carrier protein-specific FatB. The coconut LPATB 
enzyme, however, was ineffective for esterification of CoA 
forms of caprylic (8:0) or decanoic (10:0) acids to the LPA 
Sn-2 position to generate 10:0-rich TAG in an engineered 
oilseed (Wilberg et al., 2000, Planta, 212, 33-40). In addition, 
no plant LPAT2 enzymes have been previously shown to have 
significant activity with any saturated medium-chain fatty 
acids. 
0049 DGAT enzymes occur in two forms, DGAT1 and 
DGAT2, based on their primary structures. These enzymes 
also represent potential bottlenecks for the accumulation of 
high levels of saturated medium-chain fatty acids in TAG of 
engineered oilseeds. DGAT2 enzymes from plants such as 
castor bean have been shown to enhance the accumulation of 
modified fatty acids such as ricinoleic acid. However, no 
specific plant DGAT1 or DGAT2 has been previously been 
shown to be effective at promoting increased accumulation of 
saturated medium-chain fatty acids in engineered oilseeds or 
to be active with DAGs rich in medium-chain fatty acids such 
as decanoic acid (10:0). 
0050. The embodiment of this invention is the discovery of 
LPAT2 and DGAT1 genes that are demonstrated in this dis 
closure to enhance the accumulation of medium-chain fatty 
acids, in particular, C8:0 and C10:0, in TAG and in the sn-2 
position of TAG when expressed together with specialized 
FatB genes in seeds of the oilseed crop camelina (Camelina 
sativa). The co-expression of the LPAT2 genes with the 
DGAT1 genes is also shown to yield synergistic increases in 
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medium-chain fatty acid accumulation in TAG and the Sn-2 
position of TAG in transgenic plants. 
Nucleic Acids and Polypeptides 
0051 Novel nucleic acids encoding acyltransferases are 
provided herein (see, for example, SEQID NOs: 1, 3, 5, 7, or 
9). Acyltransferases (PFO1553; EC 2.3.1) are well known in 
the art and are defined as transferase enzymes that act on acyl 
groups. The acyltransferases exemplified herein include a 
lysophosphatidic acid acyltransferase (LPAT; EC 2.3.1.51) 
and a diacylglycerol acyltransferase (DGAT; EC 2.3.1.20). 
The LPAT2 and LPAT2a polypeptides disclosed herein are 
unique in that they esterify saturated C8-C16 fatty acyl-CoA, 
including a high affinity for saturated C8 and C10 fatty acyl 
CoA, at the sn-2 position of triacylglycerols (TAGs), while 
the DGAT1 polypeptides disclosed herein have unique speci 
ficity for diacylglycerols (DAGs) Substrates having a satu 
rated C10 and, to a lesser extent, a saturated C8, at the sn-2 
position. 
0052 Novel nucleic acids encoding medium-chain fatty 
acid (MCFA)-specific thioesterase, FatB polypeptides also 
are provided herein (see, for example, SEQID NO: 15). FatB 
polypeptides are a class of thioesterases (EC 3.2.1.14) that 
release C8 to C16 saturated fatty acids from acyl carrier 
protein (ACP) during denovo fatty acid synthesis. The typical 
FatB releases C16:0 from ACP, but FatBS that release other 
saturated fatty acids are known. 
0053 As used herein, nucleic acids can include DNA and 
RNA, and includes nucleic acids that contain one or more 
nucleotide analogs or backbone modifications. A nucleic acid 
can be single Stranded or double stranded, which usually 
depends upon its intended use. The novel nucleic acids pro 
vided herein encode novel polypeptides (see, for example, 
SEQID NOS: 2, 4, 6, 8, 10, or 16). Also provided are nucleic 
acids and polypeptides that differ from SEQID NOs: 1, 3, 5, 
7.9, or 15, and SEQID NOS: 2, 4, 6, 8, 10, or 16, respectively. 
Nucleic acids and polypeptides that differ in sequence from 
SEQID NOs: 1, 3, 5, 7, 9, or 15, and SEQID NOs: 2, 4, 6, 8, 
10, or 16, can have at least 50% sequence identity (e.g., at 
least 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 
84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 
94%. 95%, 96%, 97%, 98%, or 99% sequence identity) to 
SEQID NOs: 1, 3, 5, 7, 9, or 15, and SEQID NOs: 2, 4, 6, 8, 
10, or 16, respectively. 
0054. In calculating percent sequence identity, two 
sequences are aligned and the number of identical matches of 
nucleotides or amino acid residues between the two 
sequences is determined. The number of identical matches is 
divided by the length of the aligned region (i.e., the number of 
aligned nucleotides oramino acid residues) and multiplied by 
100 to arrive at a percent sequence identity value. It will be 
appreciated that the length of the aligned region can be a 
portion of one or both sequences up to the full-length size of 
the shortest sequence. It also will be appreciated that a single 
sequence can align with more than one other sequence and 
hence, can have different percent sequence identity values 
over each aligned region. 
0055. The alignment of two or more sequences to deter 
mine percent sequence identity can be performed using the 
computer program ClustalW and default parameters, which 
allows alignments of nucleic acid or polypeptide sequences to 
be carried out across their entire length (global alignment). 
Chenna et al., 2003, Nucleic Acids Res., 31 (13):3497-500. 
ClustalW calculates the best match between a query and one 
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or more subject sequences, and aligns them so that identities, 
similarities and differences can be determined. Gaps of one or 
more residues can be inserted into a query sequence, a subject 
sequence, or both, to maximize sequence alignments. Forfast 
pairwise alignment of nucleic acid sequences, the default 
parameters can be used (i.e., word size: 2; window size: 4; 
scoring method: percentage; number oftop diagonals: 4; and 
gap penalty: 5); for an alignment of multiple nucleic acid 
sequences, the following parameters can be used: gap open 
ing penalty: 10.0; gap extension penalty: 5.0; and weight 
transitions: yes. For fast pairwise alignment of polypeptide 
sequences, the following parameters can be used: word size: 
1; window size: 5; scoring method: percentage; number oftop 
diagonals: 5; and gap penalty: 3. For multiple alignment of 
polypeptide sequences, the following parameters can be used: 
weight matrix: blosum: gap opening penalty: 10.0; gap exten 
sion penalty: 0.05; hydrophilic gaps: on; hydrophilic resi 
dues: Gly, Pro, Ser, ASn, Asp, Gln, Glu, Arg, and Lys; and 
residue-specific gap penalties: on. ClustalW can be run, for 
example, at the Baylor College of Medicine Search Launcher 
website or at the European Bioinformatics Institute website 
on the World WideWeb. 
0056 Changes can be introduced into a nucleic acid mol 
ecule (e.g., SEQID NOs: 1, 3, 5, 7, 9, or 15), thereby leading 
to changes in the amino acid sequence of the encoded 
polypeptide (e.g., SEQ ID NOS: 2, 4, 6, 8, 10, or 16). For 
example, changes can be introduced into nucleic acid coding 
sequences using mutagenesis (e.g., site-directed mutagen 
esis, PCR-mediated mutagenesis) or by chemically synthe 
sizing a nucleic acid molecule having Such changes. Such 
nucleic acid changes can lead to conservative and/or non 
conservative amino acid Substitutions at one or more amino 
acid residues. A "conservative amino acid Substitution' is one 
in which one amino acid residue is replaced with a different 
amino acid residue having a similar side chain (see, for 
example, Dayhoff et al. (1978, in Atlas of Protein Sequence 
and Structure, 5(Suppl. 3):345-352), which provides fre 
quency tables for amino acid Substitutions), and a non-con 
servative Substitution is one in which an amino acid residue is 
replaced with an amino acid residue that does not have a 
similar side chain. 
0057. As used herein, an "isolated nucleic acid molecule 
is a nucleic acid molecule that is free of sequences that natu 
rally flank one or both ends of the nucleic acid in the genome 
of the organism from which the isolated nucleic acid mol 
ecule is derived (e.g., a cDNA or genomic DNA fragment 
produced by PCR or restriction endonuclease digestion). 
Such an isolated nucleic acid molecule is generally intro 
duced into a vector (e.g., a cloning vector, or an expression 
vector) for convenience of manipulation or to generate a 
fusion nucleic acid molecule, discussed in more detail below. 
In addition, an isolated nucleic acid molecule can include an 
engineered nucleic acid molecule Such as a recombinant or a 
synthetic nucleic acid molecule. 
0.058 As used herein, a “purified polypeptide is a 
polypeptide that has been separated or purified from cellular 
components that naturally accompany it. Typically, the 
polypeptide is considered “purified when it is at least 70% 
(e.g., at least 75%, 80%, 85%, 90%. 95%, or 99%) by dry 
weight, free from the polypeptides and naturally occurring 
molecules with which it is naturally associated. Since a 
polypeptide that is chemically synthesized is, by nature, sepa 
rated from the components that naturally accompany it, a 
synthetic polypeptide is “purified.” 
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0059 Nucleic acids can be isolated using techniques rou 
tine in the art. For example, nucleic acids can be isolated using 
any method including, without limitation, recombinant 
nucleic acid technology, and/or the polymerase chain reaction 
(PCR). General PCR techniques are described, for example in 
PCR Primer: A Laboratory Manual, Dieffenbach & Dveksler, 
Eds. Cold Spring Harbor Laboratory Press, 1995. Recombi 
nant nucleic acid techniques include, for example, restriction 
enzyme digestion and ligation, which can be used to isolate a 
nucleic acid. Isolated nucleic acids also can be chemically 
synthesized, either as a single nucleic acid molecule or as a 
series of oligonucleotides. 
0060 Polypeptides can be purified from natural sources 
(e.g., a biological sample) by known methods such as DEAE 
ion exchange, gel filtration, and hydroxyapatite chromatog 
raphy. A polypeptide also can be purified, for example, by 
expressing a nucleic acid in an expression vector. In addition, 
a purified polypeptide can be obtained by chemical synthesis. 
The extent of purity of a polypeptide can be measured using 
any appropriate method, e.g., column chromatography, poly 
acrylamide gel electrophoresis, or HPLC analysis. 
0061 A vector or construct containing a nucleic acid (e.g., 
a nucleic acid that encodes a polypeptide) also is provided. 
Vectors, including expression vectors, are commercially 
available or can be produced by recombinant DNA tech 
niques routine in the art. A vector containing a nucleic acid 
can have expression elements operably linked to Such a 
nucleic acid, and further can include sequences such as those 
encoding a selectable marker (e.g., an antibiotic resistance 
gene). A vector containing a nucleic acid can encode a chi 
meric or fusion polypeptide (i.e., a polypeptide operatively 
linked to a heterologous polypeptide, which can be at either 
the N-terminus or C-terminus of the polypeptide). Represen 
tative heterologous polypeptides are those that can be used in 
purification of the encoded polypeptide (e.g., 6xHis tag, glu 
tathione S-transferase (GST)) 
0062 Expression elements include nucleic acid sequences 
that direct and regulate expression of nucleic acid coding 
sequences. One example of an expression element is a pro 
moter sequence. Expression elements also can include 
introns, enhancer sequences, response elements, or inducible 
elements that modulate expression of a nucleic acid. Expres 
sion elements can be of bacterial, yeast, insect, mammalian, 
or viral origin, and vectors can contain a combination of 
elements from different origins. As used herein, operably 
linked means that a promoter or other expression element(s) 
are positioned in a vector relative to a nucleic acid in Such a 
way as to direct or regulate expression of the nucleic acid 
(e.g., in-frame). 
0063 Vectors as described herein can be introduced into a 
host cell. As used herein, “host cell refers to the particular 
cell into which the nucleic acid is introduced and also 
includes the progeny of such a cell that carry the vector. A host 
cell can be any prokaryotic or eukaryotic cell. For example, 
nucleic acids can be expressed in bacterial cells such as E. 
coli, or in insect cells, yeast or mammalian cells (such as 
Chinese hamster ovary cells (CHO) or COS cells). Other 
suitable host cells are known to those skilled in the art. Many 
methods for introducing nucleic acids into host cells, both in 
vivo and in vitro, are well knownto those skilled in the art and 
include, without limitation, electroporation, calcium phos 
phate precipitation, polyethylene glycol (PEG) transforma 
tion, heat shock, lipofection, microinjection, and viral-medi 
ated nucleic acid transfer. 
Aug. 18, 2016 
0064. Nucleic acids can be detected using any number of 
amplification techniques (see, e.g., PCR Primer: A Labora 
tory Manual, 1995, Dieffenbach & Dveksler, Eds. Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.: 
and U.S. Pat. Nos. 4,683, 195; 4,683.202; 4,800,159; and 
4.965.188) with an appropriate pair of oligonucleotides (e.g., 
primers). A number of modifications to the original PCR have 
been developed and can be used to detect a nucleic acid. 
0065 Nucleic acids also can be detected using hybridiza 
tion. Hybridization between nucleic acids is discussed in 
detail in Sambrook et al. (1989, Molecular Cloning: A Labo 
ratory Manual, 2nd Ed., Cold Spring Harbor Laboratory 
Press, Cold Spring Harbor, N.Y.; Sections 7.37-7.57, 9.47-9. 
57, 11.7-11.8, and 11.45-11.57). Sambrook et al. discloses 
suitable Southern blot conditions for oligonucleotide probes 
less than about 100 nucleotides (Sections 11.45-11.46). The 
Tm between a sequence that is less than 100 nucleotides in 
length and a second sequence can be calculated using the 
formula provided in Section 11.46. Sambrook et al. addition 
ally discloses Southern blot conditions for oligonucleotide 
probes greater than about 100 nucleotides (see Sections 9.47 
9.54). The Tm between a sequence greater than 100 nucle 
otides in length and a second sequence can be calculated 
using the formula provided in Sections 9.50-9.51 of Sam 
brook et al. 
0066. The conditions under which membranes containing 
nucleic acids are prehybridized and hybridized, as well as the 
conditions under which membranes containing nucleic acids 
are washed to remove excess and non-specifically bound 
probe, can play a significant role in the stringency of the 
hybridization. Such hybridizations and washes can be per 
formed, where appropriate, under moderate or high Strin 
gency conditions. For example, washing conditions can be 
made more stringent by decreasing the salt concentration in 
the wash Solutions and/or by increasing the temperature at 
which the washes are performed. Simply by way of example, 
high Stringency conditions typically include a wash of the 
membranes in 0.2XSSC at 65° C. 
0067. In addition, interpreting the amount of hybridization 
can be affected, for example, by the specific activity of the 
labeled oligonucleotide probe, by the number of probe-bind 
ing sites on the template nucleic acid to which the probe has 
hybridized, and by the amount of exposure of an autoradio 
graph or other detection medium. It will be readily appreci 
ated by those of ordinary skill in the art that although any 
number of hybridization and washing conditions can be used 
to examine hybridization of a probe nucleic acid molecule to 
immobilized target nucleic acids, it is more important to 
examine hybridization of a probe to target nucleic acids under 
identical hybridization, washing, and exposure conditions. 
Preferably, the target nucleic acids are on the same mem 
brane. 
0068 A nucleic acid molecule is deemed to hybridize to a 
nucleic acid but not to another nucleic acid if hybridization to 
a nucleic acid is at least 5-fold (e.g., at least 6-fold, 7-fold, 
8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-fold) greater 
than hybridization to another nucleic acid. The amount of 
hybridization can be quantitated directly on a membrane or 
from an autoradiograph using, for example, a Phosphorm 
ager or a Densitometer (Molecular Dynamics, Sunnyvale, 
Calif.). 
0069 Polypeptides can be detected using antibodies. 
Techniques for detecting polypeptides using antibodies 
include enzyme linked immunosorbent assays (ELISAS), 
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Western blots, immunoprecipitations and immunofluores 
cence. An antibody can be polyclonal or monoclonal. An 
antibody having specific binding affinity for a polypeptide 
can be generated using methods well known in the art. The 
antibody can be attached to a solid Support Such as a micro 
titer plate using methods known in the art. In the presence of 
a polypeptide, an antibody-polypeptide complex is formed. 
0070 Detection (e.g., of an amplification product, a 
hybridization complex, or a polypeptide) is usually accom 
plished using detectable labels. The term “label' is intended 
to encompass the use of direct labels as well as indirect labels. 
Detectable labels include enzymes, prosthetic groups, fluo 
rescent materials, luminescent materials, bioluminescent 
materials, and radioactive materials. 
Medium-Chain Fatty Acids and Methods of Making 
Medium-Chain Fatty Acids 
0071. The nucleic acids described herein, and the 
polypeptides encoded thereby, can be used to engineer a 
variety of useful medium-chain fatty acids and triacylglycer 
ols that incorporate Such medium-chain fatty acids. As used 
herein, medium-chain fatty acids refer to 6- to 14-carbon long 
saturated fatty acids; specifically, caprioc (C6:0), caprylic 
(C8:0), capric (C10:0), lauric (C12:0), and myristic (C14:0) 
acids. Coconut and palm-kernel oils naturally contain high 
amounts of medium-chain fatty acids. Medium-chain tria 
cylglycerols (MCTs) usually contain unsaturated 6- to 
14-carbon fatty acid esters of glycerol, but the nucleic acids 
described herein and the polypeptides encoded thereby can be 
used to produce TAGs containing predominantly C8:0, C10: 
0, or C12:0 fatty acid esters at the sn-2 position. As used 
herein, “predominantly refers to at least 20% of the TAGs 
(e.g., at least 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 
90% or 95% of the TAGs) having a C8:0 or a C10:0 at the sn-2 
position. 
0072 For example, FatBs that can generate C8 and C10 
fatty acids (e.g., ChFatB2 or CvFatB1) can be used in com 
bination with at least one of the novel acyltransferases 
described herein to strongly enhance the production of TAGs 
having a saturated C8 or C10 at the sn-2 position. Also for 
example, a FatB that can generate C14 and C16 fatty acids 
(e.g., Cpfath32) can be used in combination with at least one 
of the novel acyltransferases described herein to strongly 
enhance the production of TAGs having a saturated C14 or 
C16 at the sn-2 position. It would be appreciated that other 
FatB sequences can be used in combination with at least one 
of the acyltransferases described herein to engineer useful 
medium-chain fatty acids and the TAGs incorporating them. 
0073. Significantly, the LPATs and DGATs described 
herein have unprecedented specificity for C8 and C10 fatty 
acids. Also significantly, the combination of one of the LPAT 
sequences disclosed herein and one of the DGAT sequences 
disclosed herein, in combination with a FatB sequence, 
results in a synergistic effect on the production of fatty acids 
and, consequently, the TAGs incorporating Such fatty acids. 
Although not wishing to be bound by any particular mecha 
nism, the observed synergy likely is because the LPATs 
described herein generate higher levels of DAGs with satu 
rated fatty acids at the sn-2 position, which likely is the 
preferred substrate for DGATs described herein. 
0074 At least one of the acyltransferase sequences 
described herein can be expressed (e.g., overexpressed) in a 
transgenic organism in order to produce oils or triacylglycer 
ols one or more medium-chain fatty acids. Therefore, trans 
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genic organisms are provided that are transformed with at 
least one of the acyltransferase nucleic acid molecules 
described herein (e.g., SEQ ID NOs: 1, 3, 5, 7, or 9) or a 
functional fragment thereof, under control of a promoter that 
is able to drive expression. As discussed herein, a nucleic acid 
molecule used in a plant expression vector can have a differ 
ent sequence than a sequence described herein, which can be 
expressed as a percent sequence identity (relative to, e.g., 
SEQID NOs: 1, 3, 5, 7, or 9) or based on the conditions under 
which the sequence hybridizes to, e.g., SEQID NOs: 1, 3, 5, 
7, or 9. 
0075. As an alternative to using a full-length sequence, a 
portion of the sequence can be used that encodes a polypep 
tide fragment having the desired functionality (referred to 
hereinas a “functional fragment'). When used with respect to 
nucleic acids, it would be appreciated that it is not the nucleic 
acid fragment that possesses functionality but the encoded 
polypeptide fragment. Based on the disclosure herein, one of 
skill in the art can predict the portion(s) of a polypeptide (e.g., 
one or more domains) that may impart the desired function 
ality. 
0076. In addition to at least one of the acyltransferases 
disclosed herein, the organisms also can contain a nucleic 
acid encoding a MCFA-specific thioesterase (FatB). Numer 
ous FatB sequences are known in the art (e.g., without limi 
tation, SEQID NOs: 11 and 13), or the novel FatB sequence 
disclosed herein (e.g., SEQID NO:15) can be used. In some 
embodiments, the FatB sequence is heterologous to the 
organism; in some embodiments, the FatB sequence is endog 
enous to the organism. 
0077 Methods of introducing one or more nucleic acids 
(e.g., one or more heterologous nucleic acids, one or more 
transgenes) into cells, including plant cells, are known in the 
art and include, for example, particle bombardment, Agro 
bacterium-mediated transformation, microinjection, poly 
ethylene glycol-mediated transformation (e.g., of proto 
plasts, see, for example, Yoo et al. (2007, Nature Protocols, 
2(7): 1565-72)), liposome-mediated DNA uptake, or elec 
troporation. Following transformation of plant cells, the 
transgenic cells can be regenerated into transgenic plants. As 
described herein, expression of the transgene results in an 
organism that produces, or exhibits an increased amount of 
medium-chain fatty acids (relative to a corresponding organ 
ism not containing or not expressing the transgene). The 
transgenic organisms can be screened for the amount of 
medium-chain fatty acids, and the medium-chain fatty acids 
can be obtained (e.g., purified) from the organism. 
0078 Methods of detecting medium-chain fatty acids, and 
methods of determining the amount of one or more medium 
chain fatty acids, are known in the art and are described 
herein. For example, high performance liquid chromatogra 
phy (HPLC), gas liquid chromatography (GLC), liquid chro 
matography (LC), and ESI-MS/MS scans can be used to 
detect the presence of one or more medium-chain fatty acids 
and/or determine the amount of one or more medium-chain 
fatty acids. Lipase digestion of triacylglycerols can also be 
used to establish the content of medium-chain fatty acids at 
the Sn-2 position of triacylglycerols. 
0079. As used herein, an “increase' refers to an increase 
(e.g., a statistically significant increase) in the amount of 
medium-chain fatty acids or oils or triacylglycerols in plants 
by at least about 5% up to about 95% (e.g., about 5% to about 
10%, about 5% to about 20%, about 5% to about 50%, about 
5% to about 75%, about 10% to about 25%, about 10% to 
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about 50%, about 10% to about 90%, about 20% to about 
40%, about 20% to about 60%, about 20% to about 80%, 
about 25% to about 75%, about 50% to about 75%, about 50% 
to about 85%, about 50% to about 95%, and about 75% to 
about 95%) relative to the amount from a non-transgenic 
organism. As used herein, statistical significance refers to a 
p-value of less than 0.05, e.g., a p-value of less than 0.025 or 
a p-value of less than 0.01, using an appropriate measure of 
statistical significance, e.g., a one-tailed two sample t-test. 
0080 When the organism is a microbe, a highly express 
ing or constitutive promoter can be used to direct expression 
of the at least one acyltransferase. Transgenic microbes then 
can be cultured or fermented in order to obtain the medium 
chain fatty acids. When the organism is a plant, it generally is 
desirable, although not absolutely required, to use a seed 
specific promoter to direct expression of the at least one 
acyltransferase. Significantly, the promoters of the acyltrans 
ferases described herein are seed-specific, and thus, can be 
used to direct expression of the sequences in a transgenic 
plant. Transgenic plants having increased amounts of 
medium-chain fatty acids, compared to the amount in a cor 
responding non-transgenic plant, can be selected for use in, 
for example, a breeding program as discussed in more detail 
below. 
0081 Following transformation, transgenic To plants are 
regenerated from the transformed cells and those plants, or a 
Subsequent generation of that population (e.g., T. T. T. 
etc.), can be screened for the presence of the at least one 
acyltransferase (e.g., SEQID NOs: 1, 3, 5, 7, or 9) or for the 
phenotype (e.g., an increase in the amount of medium-chain 
fatty acids compared to a non-transgenic plant or a transgenic 
plant not expressing the transgene). Screening for plants car 
rying at least one acyltransferase can be performed using 
methods routine in the art (e.g., hybridization, amplification, 
combinations thereof) or by evaluating the phenotype (e.g., 
detecting and/or determining the amount of one or more 
medium-chain fatty acids in the plant (e.g., in the seed)). 
Generally, the presence and expression of the at least one 
acyltransferase (e.g., SEQID NOs: 1, 3, 5, 7, or 9) results in 
an increase of one or more medium-chain fatty acids in the 
plants (e.g., in seeds from the plants) compared to a corre 
sponding plant (e.g., having the same varietal background) 
lacking or not expressing the at least one acyltransferase. 
0082. A plant carrying the at least one acyltransferase 
(e.g., SEQ ID NOs: 1, 3, 5, 7, or 9) can be used in a plant 
breeding program to create novel and useful cultivars, lines, 
varieties and hybrids. Thus, in some embodiments, a T, T 
T or later generation plant containing the at least one acyl 
transferase is crossed with a second plant, and progeny of the 
cross are identified in which the at least one acyltransferase is 
present. It will be appreciated that the second plant can be one 
of the species and varieties described herein. It will also be 
appreciated that the second plant can contain the same trans 
gene or combination of transgenes as the plant to which it is 
crossed, a different transgene, or the second plant can carry a 
mutation or be wild type at the endogenous locus. Addition 
ally or alternatively, a second line can exhibit a phenotypic 
trait such as, for example, disease resistance, high yield, 
height, plant maturation, stalk size, and/or leaf number per 
plant. 
0083) Breeding is carried out using known procedures. 
DNA fingerprinting, SNP or similar technologies may be 
used in a marker-assisted selection (MAS) breeding program 
to transfer or breed the transgene(s) into other lines, varieties 
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or cultivars, as described herein. Progeny of the cross can be 
screened for the transgene(s) using methods described herein, 
and plants having the transgenes described herein (e.g., SEQ 
ID NOs: 1, 3, 5, 7, or 9) can be selected. For example, plants 
in the F or backcross generations can be screened using a 
marker developed from a sequence described herein or a 
fragment thereof, using one of the techniques listed herein. 
Seed from progeny plants also can be screened for the amount 
of one or more medium-chain fatty acids, and those plants 
having increased amounts, compared to a corresponding 
plant that lacks the transgene, can be selected. Plants identi 
fied as possessing the transgene and/or the expected pheno 
type can be backcrossed or self-pollinated to create a second 
population to be screened. Backcrossing or other breeding 
procedures can be repeated until the desired phenotype of the 
recurrent parent is recovered. 
I0084. Successful crosses yield F plants that are fertile and 
that can be backcrossed with one of the parents if desired. In 
some embodiments, a plant population in the F generation is 
screened for the transgene using standard methods (e.g., PCR 
with primers based upon the nucleic acid sequences disclosed 
herein). Selected plants are then crossed with one of the 
parents and the first backcross (BC) generation plants are 
self-pollinated to produce a BCF population that is again 
screened for the transgene or the phenotype. The process of 
backcrossing, self-pollination, and screening is repeated, for 
example, at least four times until the final Screening produces 
a plant that is fertile and reasonably similar to the recurrent 
parent. This plant, if desired, is self-pollinated and the prog 
eny are Subsequently screened again to confirm that the plant 
contains the transgene and exhibits the expected phenotype. 
Breeder's seed of the selected plant can be produced using 
standard methods including, for example, field testing, con 
firmation of the presence of the transgene, and/or chemical 
analyses of the plant (e.g., of the seed) to determine the level 
of medium-chain fatty acids. 
I0085. The result of a plant breeding program using the 
transgenic plants described herein are novel and useful culti 
vars, varieties, lines, and hybrids. As used herein, the term 
“variety” refers to a population of plants that share constant 
characteristics which separate them from other plants of the 
same species. A variety is often, although not always, sold 
commercially. While possessing one or more distinctive 
traits, a variety is further characterized by a very small overall 
variation between individuals within that variety. A "pure 
line' variety may be created by several generations of self 
pollination and selection, or vegetative propagation from a 
single parent using tissue or cell culture techniques. A "line.” 
as distinguished from a variety, most often denotes a group of 
plants used non-commercially, for example, in plant research. 
A line typically displays little overall variation between indi 
viduals for one or more traits of interest, although there may 
be some variation between individuals for other traits. 
I0086 A variety can be essentially derived from another 
line or variety. As defined by the International Convention for 
the Protection of New Varieties of Plants (Dec. 2, 1961, as 
revised at Geneva on Nov. 10, 1972. On Oct. 23, 1978, and on 
Mar. 19, 1991), a variety is “essentially derived from an 
initial variety if: a) it is predominantly derived from the initial 
variety, or from a variety that is predominantly derived from 
the initial variety, while retaining the expression of the essen 
tial characteristics that result from the genotype or combina 
tion of genotypes of the initial variety; b) it is clearly distin 
guishable from the initial variety; and c) except for the 
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differences which result from the act of derivation, it confirms 
to the initial variety in the expression of the essential charac 
teristics that result from the genotype or combination of geno 
types of the initial variety. Essentially derived varieties can be 
obtained, for example, by the selection of a natural or induced 
mutant, a Somaclonal variant, a variant individual plant from 
the initial variety, backcrossing, or transformation. 
0087 Hybrids can be produced by preventing self-polli 
nation of female parent plants (i.e., seed parents) of a first 
variety, permitting pollen from male parent plants of a second 
variety to fertilize the female parent plants, and allowing F 
hybrid seeds to form on the female plants. Self-pollination of 
female plants can be prevented by emasculating the flowers at 
an early stage of flower development. Alternatively, pollen 
formation can be prevented on the female parent plants using 
a form of male sterility. For example, male sterility can be 
produced by cytoplasmic male sterility (CMS), nuclear male 
sterility, genetic male sterility, molecular male sterility 
wherein a transgene inhibits microsporogenesis and/or pollen 
formation, or self-incompatibility. Female parent plants con 
taining CMS are particularly useful. In embodiments in 
which the female parent plants are CMS, the male parent 
plants typically contain a fertility restorer gene to ensure that 
the F hybrids are fertile. In other embodiments in which the 
female parents are CMS, male parents can be used that do not 
contain a fertility restorer. F hybrids produced from such 
parents are male sterile. Male sterile hybrid seed can be 
interplanted with male fertile seed to provide pollen for seed 
set on the resulting male sterile plants. 
0088 Varieties, lines and cultivars described herein can be 
used to form single-cross F hybrids. In such embodiments, 
the plants of the parent varieties can be grown as Substantially 
homogeneous adjoining populations to facilitate natural 
cross-pollination from the male parent plants to the female 
parent plants. The F seed formed on the female parent plants 
is selectively harvested by conventional means. One also can 
grow the two parent plant varieties in bulk and harvestablend 
of F hybrid seed formed on the female parent and seed 
formed upon the male parent as the result of self-pollination. 
Alternatively, three-way crosses can be carried out wherein a 
single-cross F hybrid is used as a female parent and is 
crossed with a different male parent. As another alternative, 
double-cross hybrids can be created wherein the F progeny 
of two different single-crosses are themselves crossed. Self 
incompatibility can be used to particular advantage to prevent 
self-pollination of female parents when forming a double 
cross hybrid. 
0089. The microbial organisms used in the methods 
described herein include, without limitation, bacteria (E. coli, 
Pseudomonas sp.), cyanobacteria (Synechocystis sp), and 
green microalgae (C. reinhardtii, Phaeodactylum tricornu 
tum, Chlorella sp., Nannochloropsis sp.) species, fungal (Yar 
rowia lipolytica, Saccharomyces cerevisiae) species. The 
plants used in the methods described herein can be oilseed 
plants such as, without limitation, Camelina spp. (e.g., Cam 
elina sativa, Camelina alyssum, Camelina rumelica) or other 
Brassicaceae spp. (e.g., Brassica oleracea, Brassica rapa, 
Brassica napus, B. Carinata), Limnanthes alba (meadow 
foam), Glycine max (soybean), Linum spp. (e.g., Linum usi 
tatissimum, flax), Crambe spp. (e.g. Crambe abyssinica), 
Ricinus communis (castor bean), Gossypium spp. (e.g. Gos 
sypium hirsutum cotton), or non-oilseed plants such as, with 
out limitation, legumes (e.g., peas, beans), tuberous crops 
(potato, cassava), or other crop plant. 
Aug. 18, 2016 
(0090. The MCFAS or TAGs comprising MCFAs produced 
in the methods herein can be used in any number of products 
in which a medium-chain fatty acid or a TAG containing Such 
a medium-chain fatty acid is desired. Such products include, 
without limitation, biofuel and/or jet fuel. For example, veg 
etable oils with TAGs containing fatty acid chains having 10 
or less carbons are more desirable feedstocks for the biofuel 
industry due to their lower viscosity and because such veg 
etable oils may not require trans-esterification, which is usu 
ally a required step when converting vegetable oils to biodie 
sel. In addition, the MCFAS or the TAGs comprising MCFAs 
produced as described herein can be used in detergents, cos 
metics, Surfactants, or feedstocks for preparation of other 
specialized chemicals. 
0091. In addition, in some embodiments, one or more of 
the acyltransferases described herein can be used in industrial 
inter-esterification of fatty acids to generate particular TAGs 
or one or more of the acyltransferases described herein can be 
used in a bioreactor (e.g., one or more of the acyltransferases 
described herein can be immobilized) to make particular 
TAGs for specialized nutritional or industrial applications. 
0092. In accordance with the present invention, there may 
be employed conventional molecular biology, microbiology, 
biochemical, and recombinant DNA techniques within the 
skill of the art. Such techniques are explained fully in the 
literature. The invention will be further described in the fol 
lowing examples, which do not limit the scope of the methods 
and compositions of matter described in the claims. 
EXAMPLES 
Part A 
Example 1 
Plant Material, Growth and Transformation 
Conditions 
I0093 Camelina sativa seed was sowed into 81 cm square 
green plastic pots with Fafard Germination Mix based soil. 
Natural ambient light was Supplemented in the greenhouses 
with a combination of metal halide and high pressure Sodium 
lights. Lights was provided for a 14 hour day-length. During 
the daytime temperatures were set at a range of 24°C.-26°C. 
and during the nighttime temperatures were set at a range 18' 
C.-20° C. When outdoor temperatures were above 29° C. the 
supplemental lights were shut off to reduce the need for extra 
cooling. Agrobacterium tumefaciens cells (strain C58C1) 
were transformed with the binary vectors containing LPAT 
cDNA by the electroporation. Camelina plants were trans 
formed by floral dip followed by vacuum infiltration and a 
fluorescent protein (Dsked) was used as a visual selection 
marker (Lu & Kang, 2008, Plant Cell Rep. 27:273-8). Seg 
regation analyses were performed on the T2 showed fluores 
cence seeds to determine the number of T-DNA insertion loci. 
Plants homozygous for the transgene were identified by 
screening T3 seeds for 100% red fluorescence. 
Example 2 
RNA Isolation from Cuphea Species and cDNA 
Conversion 
(0094) Total RNAs were isolated from different Cuphea 
tissues such as roots, stems, leaves, flowers and developing 
seeds using slightly modified methods described in the pre 
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vious report (Chang et al., 1993, Plant Mol. Biol. Report. 
11:113-6) and RNeasy Plant Mini Kit (Qiagen). The first step 
was performed by the CTAB-based procedure. A pre-heated 
10 ml of extraction buffer (2% w/v CTAB, 2% w/v PVP, 2 M 
NaCl, 100 mM Tris-HCl pH 8.0, 25 mM EDTA pH 8.0 and 
0.05% w/v of spermidine) was added to the sample (200-300 
mg) ground in liquid nitrogen, mixed vigorously by Vortexing 
and incubated at 65° C. for 10 min. The sample was divided 
into several new microcentrifuge tubes. An equal Volume of 
chloroform was added and the tubes, mixed vigorously and 
then centrifuged at 13,000 rpm for 10 min at 4° C. The 
Supernatant was transferred to new microcentrifuge tubes and 
!/3 volume of 8 MLiCl was added. The mixture was incubated 
in ice for overnight, and the RNA was selectively collected 
after centrifugation at 13000 rpm for 1 hour at 4°C. The pellet 
was resuspended in 500 ul of RLT buffer in RNeasy Plant 
Mini Kit and was then carried out as indicated in the manu 
facturers handbook including DNase I treatment. The first 
strand cDNA was synthesized from 2 ug total RNA using 
RevertAid First Strand cDNA Synthesis Kit (Thermo Scien 
tific) with oligo-(dT) primer. 
Example 3 
Confocal Laser Scanning Microscope 
0095. The expression of transient fluorescent fusion pro 
teins in tobacco leaves was performed using the agro-infiltra 
tion methods as described previously (Sparkes et al., 2006, 
Nature Protocols, 1:2019-25). Two days after infiltration, the 
abaxial leaf surface was observed with a confocal laser scan 
ning microscope (Olympus). ForYFP and mCherry, the exci 
tation wavelengths were respectively 488 nm and 545 nm, 
and the emitted fluorescence was collected at 495-530 nm. 
and 565-600 nm, respectively. 
Example 4 
Complementation of Cuphea LPAT cDNAs by 
Expression in Escherichia coli Mutant 
0096. The thermo-sensitive strain, E. coli JC201, was used 
to complement the deficient of LPAT activity (Coleman, 
1992, Mol. Gen. Genet., 232:295-303). The Cuphea LPAT 
cDNAs were cloned into the into the pBluescript SK multi 
cloning site using SacI and Not. JC201 was transformed via 
heat shock and was selected on amplicillin plates at 30° C. 
Complementing colonies were inoculated into starter cultures 
and grown to an optical density at 600 nm of 0.5 at 30°C. with 
or without 1 mM isopropylthio-f-galactoside (IPTG). Ali 
quots were grown in the presence of IPTG at 30° C. and 44 
C., and growth curves were constructed using data obtained 
from three individual complementation experiments. 
Example 5 
Fatty Acid Analysis of Seed Oils 
0097. Fatty acid methyl esters (FAMEs) were generated 
by grinding 10 mg of dry seeds in 2 mL of 2.5% H2SO4 (v/v) 
in methanol including 900 ug of tri 17:0-TAG (Nu-Chek Prep, 
Elysian, Minn., USA) in toluene (10 mg/mL) as an internal 
standard and heated for 45 min at 90° C. in tightly capped 
tubes. Following cooling, 1.5 mL of water and 1.5 mL hexane 
were added to tubes and mixed vigorously. The organic phase 
was transferred to autosampler vials and analyzed on an Agi 
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lent Technologies 7890A gas chromatograph (GC) fitted with 
a 30 m length}x0.25 mm inner diameter HP-INNOWax col 
umn (Agilent, Santa Clara, Calif., USA) using H2 carrier gas. 
The GC was programmed for an initial temperature of 90° C. 
(1 minhold) followed by an increase of 30° C. min-1 to 235° 
C. and maintained for a further 5 min. Detection was achieved 
using flame ionization. 
Example 6 
Neutral Loss ESI-MS/MS Analysis 
0098. Mass spectrometry analyses were conducted using 
an Applied Biosystems (Foster City, Calif.) 4000 QTRAP 
linear ion trap quadrupole mass spectrometer to characterize 
TAG molecular species. The total neutral lipid extract for 
ESI-MS/MS analysis was prepared as described for seed oil 
content measurement below but without added internal stan 
dard and diluted 1:5000 in waterfisopropyl alcohol/methanol 
(55:35:10 V/v/v) containing 25 mm ammonium formate and 4 
LL/L formic acid and directly infused into the mass spectrom 
eter at a rate of 20 Jul per minute. Instrument settings were as 
follows: Source temperature 400°C., ESI needle voltage 5.5 
kV (positive mode), desolvation potential (DP) 90, entrance 
potential (EP) 10, Curtain gas (CUR) 10, and gas 1 (GS1) 50 
arbitrary units, gas 2 (GS2) 40 arbitrary units. Neutral loss 
spectra showing the loss of a specific fatty acid from TAG 
species were generated by monitoring the loss of 189.1 m/z. 
(for C10:0) and 245.1 m/z (for C14:0). Scans were taken over 
a mass range of 500-1475 m/z, with a cycle time of 3 s. Data 
was collected for five cycles. 
Example 7 
RNA. Isolation from Developing Seeds and cDNA 
Library Construction 
0099 Total RNA was isolated from Cuphea pulcherrima 
and Cuphea Viscosleaves and developing seeds collected 
from greenhouse grown plants and immediately frozen in 
liquid nitrogen and stored at -80°C. until use in RNA isola 
tion. Total RNA was isolated according to a method described 
previously (Mattheus et al., 2003, Phytochemical Analysis, 
14:209-15; Suzuki et al., 2004, Biotechniques, 37:542-44). In 
brief, developing seeds were grounded to a fine powder in 
liquid nitrogen. The powders were transferred to a chilled 
centrifuge tube containing cold extraction buffer consisting 
of 100 mM Tris-HCl, pH 8.0, 50 mMethylenebis (oxyethyl 
enenitrilo) tetraacetic acid, pH 8.0, 100 mM sodium chloride, 
1% 6-(p-toluidino)-2-naphthalenesulphonic acid, 6% sodium 
p-aminosalicylic acid, 1% SDS, 1% PVP-40, 3% PVPP:chlo 
roform and 1% B-mercaptoethanol. The sample was centri 
fuged for 10 min with Sorvall SS-34 rotor, 10500 rpm at 4°C. 
The Supernatant was transferred to a fresh tube. An equal 
Volume of chloroform was added and the mixture was Vor 
texed for 2 min, centrifuged for 10 min at 10500 rpm and 4° 
C. The aqueous phase was transferred to a fresh tube. The 
aqueous fraction was extracted twice with phenol: chloroform 
(1:1, V/v), and extracted once with chloroform. The RNA was 
precipitated overnight with 0.1 volume of 3M sodium acetate 
(pH 5.2) and 2.5 volume of 95% ethanol at -20°C. The RNA 
was precipitated by centrifugation for 30 min at 10500 rpm 
and 4° C. rinsed once with 70% ethanol, briefly dried, and 
dissolved in DEPC-water. 
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Example 8-454 
Transcriptome Analysis 
0100 200 ng of polyA+-enriched RNA prepared from 
developing seeds of Cuphea pulcherrima and Cuphea visco 
Sissma was used in the preparation of a single sequencing 
library with custom adaptors according to methods of 
Nguyen, H.T., Silva, J. E., Podicheti, R., Macrander, J., Yang, 
W., Nazarenus, T. J., Nam, J. W., Jaworski, J. G., Lu, C, 
Scheffler, B. E., Mockaitis, K & Cahoon, E. B. (2013). The 
double-stranded cDNA library intermediate was partially 
normalized by DSN treatment (Evrogen) to reduce the rep 
resentation of the transcripts of greatest abundance. Shearing 
prior to adaptor ligation was by nebulization (30 sec. 30 psi). 
The final library was assessed on a Bioanalyzer DNA7500 
chip (Agilent) and showed a peak size of 660 bp. 
0101 Emulsion PCR and sequencing was done according 
to the manufacturer (Rochef.454 Sequencing). Two regions of 
two-region plus three regions of four-region GS-FLX Tita 
nium Pico TitreTM plate were run to 800 cycles. 
0102 The Cuphea pulcherrima and Cuphea viscosissma 
transcriptome assemblies were matched by BLASTX using 
BLOSUM62 scoring matrix and a word size of 3, to protein 
sequences of TAIR 10 representative gene models (Arabidop 
sis.org on the WorldWideWeb) with an E-value limit of 1 e-5. 
The top hit(s) for each query sequence was retained based on 
best bit score and E-value. Secondly TAIR 10 models (above) 
were matched to assembly elements (isotigs and singletons) 
using tBLASTN with an E-value limit of 1 e-5. Candidate 
acyl lipid metabolism gene sequences were retrieved from 
BLAST result sets above were trimmed to include only these 
genes. The best isotig for each isogroup was retained, trim 
ming outputative alternative transcripts of the same gene (as 
described in Nguyen et al., 2013, Plant Biotechnol. J., 11(6), 
759-769. 
Example 9 
Isolation of Multiple Putative LPAT Paralogs in 
Cuphea Species 
0103) To isolate specialized LPAT for medium chain acyl 
CoA, we performed the RNA sequencing and assembly of 
over 2 million 454 sequencing pyrosequencing reads from the 
developing seeds of C. pulcherrima (recently re-classified as 
C. avigera var. pulcherrima) and C. viscosissima. Nucleotide 
sequence similarity to Arabidopsis LPAT2 was used for iden 
tification of potential LPAT orthologs. Six full-lengths of 
LPAT candidate genes were isolated in the 454 sequencing 
transcriptome of C. pulcherrima, and one full-length of LPAT 
candidate gene was found in the 454 sequencing transcrip 
tome of C. viscosissima. We used the 7 full-lengths of putative 
LPAT genes for further studies. 
0104. The evolutionary relationship of cuphea LPAT 
genes was investigated based on their deduced amino acid 
sequences to collect more information about relationships 
and to predict function for TAG accumulation. The sequences 
were aligned with putative orthologs of higher plants, which 
were described by Manas-Fernandez et al. (2013, Europ. J. 
Lipid Sci. Technol. 115:1334-6) and Arroyo-Caro et al. 
(2013, Plant Sci., 199:29-40), and obtained the sequences 
from the protein database of the National Center for Biotech 
nology Information (NCBI). LPATs have been sub-grouped 
by plastid LPAT (LPAT1) and microsomal LPAT, and then the 
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latter was further categorized into two classes, A and B. The 
class A microsomal LPATs are typical enzymes involved in 
synthesis of membrane glycerolipids, they show ubiquitous 
expression in plants and have a substrate preference for 18:1- 
CoA. Based on the category of Arabidopsis LPATs, the class 
A microsomal LPATs were further divided into 2 subgroups 
as LPAT2/LPAT3 group and LPAT4/LPAT5 group. The class 
B microsomal LPAT (LPATB) is classified as a seed-specific 
isoform and is found in plants accumulating unusual fatty 
acids in their seed oil. Even though LPATB is a microsomal 
LPAT, the class has a closer relationship with plastidal LPAT1 
than other plant groups. However, LPATB is closer to the 
enzyme of other organisms, such as E. coli, yeast, and human. 
0105 Four genes of class A LPAT, one gene of LPATB, 
and one gene of LPAT1 were found in C. pulcherrima. Based 
on the classification, these LPATs were named as CpuLPAT1, 
CpuLPAT2a, CpulPAT2b. CpuLPAT2c, CpuLPAT3 and 
CpulPATB (FIG. 1). One LPAT gene from C. viscosissima 
was isolated, classified as class A, and named as CVLPAT2 
(FIG. 1). CpuLPATB belonged to the same group as Cn LPAT, 
which was isolated in coconut and related to increase of lauric 
acid by incorporating this fatty acid into the Sn-2 position of 
TAG in transgenic plants seeds (Knutzon, et al., 1999, Plant 
Physiol. 109:999-1006). Based on the relationship between 
coconut LPATB and MCFA, we assumed that CpuLPATB 
might involve the increase of MCFA in TAG. So the studies 
were focused to reveal the function of CpulPATB. Because 
CVLPAT2 was the only LPAT gene isolated from C. viscosis 
sima, the functional studies of CvLPAT2 were performed in 
parallel. 
Example 10 
Acyltransferase Motifs and Topology of 
Transmembrane Domain in Cuphea LPATs 
010.6 An amino acid alignment reveals a high level of 
amino acid identity among plant LPATBs (FIG. 2A). The 
LPLAT-AGPAT-like domain of CpuLPATB shared 82%, 
79%, 77%, 74% and 70% identities with Vitis vinifera (XP 
002278280), Ricinus communis AFR42414, Oryza sativa 
(CAH66825), Cocos nucifera Q42670, and Limnanthes 
douglasii Q42870, respectively. The domain showed a low 
identity with other organisms such as 40% (Homo sapiens, 
NP006402), 39% (Homo sapiens, NP006403), 36% (Saccha 
romyces cerevisiae, SLC1, P33333), and 34% (Escherichia 
coli, PlsC, AAA24397). We predicted that there were 4 con 
served acyltransferase motifs in CpulPATB, which are 
NH(X). D (motif I, residues 137-143), GHLRIDR (motif II, 
residues 178-183), FPEGTR (motif III, residues 210-215), 
and LPIVPIVL (motif IV, residues 237-244) (FIG. 7A). 
These are significantly important on acyltransferase activi 
ties. Hydrophobic motif II was first characterized as an acyl 
CoA-binding site in animal cells and might modulate acyl 
CoA selectivity and residue “EGT in motif III has been 
presumed to be involved in the binding of the LPA. 
0107 To predict transmembrane domain sequences, struc 
tural analysis of the gene model-translated protein sequences 
was carried out in silico using SOSUI bp.nuap.nagoya-u.ac. 
jp/sosui?on the World Wide Web, PSORTII psort.hgc.jp/ 
form2.html on the World WideWeb, HMMTOP enzim.hu/ 
hmmtop?on the World WideWeb, and TMHMM server 2.0 
cbs.dtu.dk/services/TMHMM/ on the World WideWeb. All 
programs predicted only one transmembrane domain in 
CpulPATB in a similar region (FIG.7B). Based on the analy 
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sis of motif and transmembrane domain, the predicted topol 
ogy of CpuLPATB was presented in FIG. 7C, where all acyl 
transferase motifs were on the cytosolic side of the ER 
membrane. 
0108. The deduced amino acid sequence alignment of 
CvLPAT2 with CpuLPAT2a, CpuLPAT2b CpuLPAT2c, and 
CpulPAT3 showed the amino acid identities as 82%, 79%, 
79% and 66%, respectively, in full amino acid sequences, and 
87%, 79%, 79% and 66%, respectively, in LPLAT-AGPAT 
like domain. The amino acid identity between CpulPAT2b 
and CpuLPAT2c was the highest at 97% in LPLAT-AGPAT 
like domain. The key motifs in LPLAT-AGPAT-like domains 
were conserved well among the LPAT2s in diverse plant 
species (FIG. 8A). As for Motif I NH(X), D and motif III 
(FPEGTR), the same sequences with LPATTB, were 
observed in CVLPAT2 and in LPAT2/3 group from C. pull 
cherrima. Motif II (LPVLGW) and motif IV (NVLIPRT 
KGFV) were conserved in plant LPAT2/3 group, but those 
sequences were completely different with the LPATB's. 
There was a putative tyrosine phosphate site in motif VRCX) 
Y(X). A from CvLPAT2 like the other LPAT2/3 group. 
Transmembrane domain of CVLAAPT2 was predicted as dif 
ferent numbers by different programs; 4 by SOSUI, 3 by 
PSORTII and HMMTOP and 5 by TMHMM (FIG. 8B). All 
programs predicted the N-terminal located in cytosol and 
C-terminal located in the ER lumen. Therefore, we predicted 
that there are five transmembrane domains in CvLPAT2 as 
seen in caster bean and presented the predicted topology of 
CVLPAT2 in FIG. 8C, where motif I is located in cytosol and 
motif II-IV is located in the ER lumen by separating the third 
transmembrane domain. 
Example 11 
Tissue-Specific Expression of Cuphea LPAT 
Isoforms 
0109 Different LPAT isoforms showed the various 
expression patterns and levels in the diverse tissues of a plant. 
Because LPAT has been considered a narrow substrate speci 
ficity, tissue specific expression is one of the clues to presume 
their function. RT-PCR was performed using cDNAs from 
diverse tissues, such as roots, stems, leaves, flowers and 
developing seeds, to investigate the tissue specificity and the 
expression level of LPAT genes in C. pulcherrima and C. 
viscosissima (FIG. 2). The transcripts of CpulPAT1 were 
abundant in all tested tissues except developing seeds. 
CpulPAT2b and CpuPAT3 showed ubiquitous expression 
patterns with a low expression levels. CpulPAT2c was unde 
tectable at the same PCR cycle numbers as other LPAT genes, 
however, when PCR cycle numbers were increased it was 
slightly detected in all tissues tested. Interestingly, 
CpulPAT2a and CVLPAT2, which have very high sequence 
similarity (82% in amino acid), showed the developing seed 
specific expressions. CpuPATB was also exclusively 
detected in the developing seeds. These results indicate that 
CpuLPATB, CpuLPAT2a and Cv PAT2 might be involved in 
the accumulation of MCFAs at the sn-2 position of TAG. 
Example 12 
CpuLPATB, CpuLPAT2a, and CvLPAT2 Localize in 
the ER 
0110. The ER localization of LPAT2 was confirmed in 
Arabidopsis and Brasicca by immunofluorescence micros 
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copy of tapetum cells and by immunoblotting of Subcellular 
fraction. We investigated the subcellular localization of 
CpuLPAT2a, CpuLPATB, and CvLPAT2 by using a laser 
scanning confocal microscope. Yellow fluorescence protein 
(YFP) was fused with C-terminal of eachLPAT driven by 35S 
promoter. Each pro35S:LPAT:YFP was transiently co-ex 
pressed with the ER-rk CD3-959 as the ER marker (FIG. 
3A-C) in tobacco leaves by agro-infiltration method. YFP 
signals of CpuLPAT2a, CpuLPATB, and CvLPAT2 were 
detected as the reticular shape and co-localized with ER 
marker. The result demonstrated that CpulPAT2a, Cpull 
PATB, and CvLPAT2 are microsomal LPAT localized in the 
ER. We also tested the subcellular localization of CpuLPAT1, 
which is classified as a plastidal form. YFP signal of Cpull 
PAT1 was detected in the out membrane of chloroplasts (FIG. 
3D). 
Example 13 
CpulPATB Complemented the E. coli Mutant, 
JC2O1 
0111. To test the activities of Cuphea. LPATs, a comple 
mentation test was performed in an E. coli JC201 mutant, 
which is a temperature-sensitive mutant of plsC and able to 
grow at 30°C., but not at 42°C. The full-length open reading 
frames of Cuphea LPATs were cloned into the pEBluescript 
SK vector. FIG. 4A showed that all Cuphea LPATs and an 
empty vector grew at 30° C. Occasionally the JC201 cells 
with an empty vector grew at 42°C., and we increased the 
incubation temperature as 44° C. Only JC201 containing 
CpulPATB was able to grow at 44°C., but few colonies were 
observed in the JC201 containing other LPATs (FIG. 4A). To 
confirm the result, we tested their growth rate by measuring 
the ODconcentration in process of time. As seen in FIG. 4B, 
the cell concentration of JC201 increased in all tested 
Cuphea. LPATs and empty vector control at 30°C. However, 
only CpulPATB showed the increase of OD concentration at 
44° C. We tested the LPAT activity in the inducible vector, 
pET-duet, but the results were the same as above, even in the 
presence or absence of IPTG, Only CpulPATB comple 
mented the E. coli mutant JC201 a LPAT activity. This result 
was correlated with the amino acid homology of LPATs 
between plant and E. coli. CpulPATB shares the most similar 
homology with E. coli LPAT (34% in domain). 
Example 14 
CpuLPATB and CvLPAT2 Preferentially 
Incorporated 14:0 and 10:0, Respectively, into the 
Sn-2 Position of TAG 
0112 To investigate the activities of Cuphea LPATs in 
planta and its utility for oilseed metabolic engineering, the 
CpulPATB and CVLPAT2 genes were introduced into Cam 
elina along with the variant FatB thioesterase genes. CpFatB2 
is 14:0 specific thioesterase of Cuphea palustris (Dehesh et 
al., 1996, Plant Physiol. 110:203-10) and ChFatB2 is 8:0 and 
10:0 specific FatB thioesterase of Cuphea hookeriana (De 
hesh et al., 1996, The Plant J., 9:167-72). The seed-specific 
glycinin promoter was used to drive the CpuLPATB and the 
seed-specific oleosin promoter was used to drive the CVL 
PAT2 for exclusive gene expression in seed. Lauric acid 
specific CnLPAT was used for a comparison with CpulPATB 
and CVLPAT2. The expression of CpFatB2 in Camelina 
showed 26.3 mol % of 14:0 fatty acid. When Cpfath32 was 
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co-experessed with CnLPAT, CpuLPATB or CvLPAT2, the 
levels of 14:0 fatty acid were further increased as 33.1 mol%. 
36.5 mol % or 32.9 mol %, respectively. The expression of 
ChFatB2 in Camelina showed 7.4 mol % of 10:0 fatty acid. 
Co-expression of ChFatB2 with CnLPAT or CvLPAT2 
increased the 10:0 fatty acid as 10.2 mol % or 11.8 mol %, 
respectively. However, CpuLPATB didn't increase the 10:0 
fatty acid with ChFatB2 (FIG. 5). The positional distribution 
of the MCFA was also determined in TAG. Trace amounts of 
16:0 and 18:0 were detected at the sn-2 position of TAG in 
wild type. The composition of MCFA at the sn-2 position of 
TAG was 2.9 mol% (14:0) and 1.1 mol% (16:0) in Cpfath32 
Camelina seeds. Myristic acid the sn-2 position of TAG from 
CpFatB2 Camelina seeds was significantly increased up to 
14.2 mol% with CnLPAT, 19.7 mol % with CpuLPATB, and 
14.8 mol % with CvLPAT2 (FIG. 5B). The sn-2 position of 
TAG in ChFatB2 was not occupied by any MCFA or saturated 
fatty acid. Co-expression of ChFatB2 with CvLPAT2 resulted 
in the significant increase of 10:0 (15.4 mol %) at the sn-2 
position of TAG. However, 10:0 fatty acid was barely 
detected in the coexpression line of ChFatB2 and Cn PAT. 
CpuLPATB didn't effect on the increase of 10:0 fatty acid 
with ChFatB2 in the transgenic Camelina seeds. These results 
indicate that CpuLPATB and CVLPAT2 enhance the accumu 
lation of the saturated MCFAs in the TAG of Camelina seed 
by incorporating medium chain acyl-CoA into the Sn-2 posi 
tion of LPA. CpulPATB has a preference toward 14:0 fatty 
acid and CVLPAT2 has a preference toward myristic acid and 
capric acid. 
Example 15 
The Distribution of MCFA in TAG Molecular 
Species 
0113 To further investigate the metabolism of MCFA in 
transgenic Camelina seeds, we performed ESI-MS analysis 
for the molecular species of TAG from Camelina producing 
the FatBTE. Absolute peak intensity of mass spectra of TAG 
species from seeds expressing the FatBTE and LPAT were 
presented in FIG. 6 and FIG. 10. TAG species with at least one 
14:0 represent in plants expressing Cpfath32 with CnLPAT, 
CpuLPATB, and CvLPAT2, respectively, while any MCFA 
was not detected in the TAG in wild-type Camelina (FIG. 6). 
The levels of tri-MCFA-TAG species increased when 
CpFatB2 expressed with LPATs and the highest amount tri 
MCFA-TAG species was observed in CvLPAT2. Tri-MCFA 
TAG species in transgenic Camelina seeds confirmed that 
tested LPATs contain the preference to saturated MCFAs and 
CVLPAT2 is the best FatBTE for those Substrates. 
Part B 
Example 16 
Cloning Cpl DGAT1 Sequence from C. pulcherrima 
0114. The Cpl DGAT1 gene sequence was identified in the 
C. pulcherrima 454 sequence data generated as described 
before (Nguyen et al., 2013, Plant Biotechnol.J., 11:759-69). 
The ORF designated as Cpl DGAT1 of 1482 bp encoding 484 
amino acids was PCR amplified from C. pulcherrima cDNA 
using the gene specific primers. 
0115 For expression in yeast the native version of Cpl D 
GAT1 ORF was amplified using the primer pair 
CpDGAT1BamHIf and CplDGAT1Xbair. The ORFs for N 
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terminus truncated and mutated versions were generated 
using the forward primers Cpl DGAT1 trunc BamHI and 
CpDGAT1AlaBamHIf, respectively. The ORF for the trun 
cated version (Cp)GAT1 trunc) of Cpl DGAT1 is 70 amino 
acids shorter at N terminus than the native version. The align 
ment showed that the 70 amino acid N terminus of Cpl DGAT1 
is unique and is different from that of other DGAT1s while the 
amino acid sequence downstream the 70 amino acids is 
highly similar to that of DGAT1s from A. thaliana, O. euro 
pea, B. napus and O. sativa. The length of the differing N 
terminus region of the DGAT1s from different plant species 
varies. In the mutated version the CAT coding for His was 
replaced by GAG coding for Ala in the forward primer, 
CpGAT1 AlaBamHIf. Thus three constructs pYes2 Cpl D 
GAT1, pYes2 CplDGAT1Ala, and pYes2 CpDGAT1 trunc 
were made for expression in yeast. 
0116 For generating plant transformation vectors the 
ORF encoding for Cpl DGAT1 and CpGAT1 trunc were sub 
cloned into NotI sites of pKMS3 vector generating Glycinin 
promoter and terminator containing CpGAT1 gene cassette. 
The cassette was subsequently released by AscI to be cloned 
into Mlul site of plBinClyRed3+CvFatB1 yielding pBinG 
lyRed3 CvFatB1+CpDGAT1 or pBinGlyRed3 CvFatB1+ 
CpGAT1 trunc. The backbone of the vector is derived from 
pCAMBIA0380 and was engineered with the DSRed marker 
gene under the control of the constitutively-expressed cassava 
mosaic virus promoter for selection of transgenic seeds by 
fluorescence (Lu and Kang, 2008, Plant Cell Rep. 27:273-8). 
Similarly, A. thaliana DGAT1 was subcloned into the binary 
vector generating pBinGlyRed3 CvPat31+Athl)GAT1 for 
transformation into Camelina. 
Example 17 
Phylogenetic Analysis 
0117. An unrooted phylogenetic tree of Cpl DGAT1 
deduced amino acid sequence along with other amino acid 
sequences homologous to DGAT1 or DGAT2 including sev 
eral functionally characterized ones was constructed. The 
functional and phylogenetic relationships were identified by 
the neighbor joining program in MEGA4 (Tamura et al., 
2007, Mol. Biol. Evol., 24:1596-9). The bootstrap analysis 
was performed with 1,000 replicates. 
Example 18 
Yeast Transformation and Selection 
0118. The constructs pYes2 CplDGAT1, pYes2 
CpGAT1 Ala, and pYes2 Cpl DGAT1 trunc were trans 
formed into S. cerevisiae strain H1246 (W303; MATC. are 1 
A: HIS3 are2-A::LEU2dga1:KanMX4 lro1-A::TRP1 ADE2 
met ura3) (Sandager et al., 2002, J. Biol. Chem..., 277:6478 
82) using PEG/lithium acetate method (Gietz et al., 1995, 
Yeast, 11:355-60). The yeast cells harboring the empty pYes2 
vector were used as negative control. Transformants were 
selected by uracil prototrophy on yeast synthetic medium 
(YSM) containing 2% (w/v) glucose and lacking uracil (Invit 
rogen, Carlsbad, Calif. USA). For functional expressionYSM 
containing 2% (w/v) raffinose was inoculated with the yeast 
transformants and grown at 28°C. for 24h in a shaker at 350 
rpm. For induction, YSM containing 2% (w/v) galactose was 
inoculated with raffinose-grown cultures to obtain an OD of 
0.2 at 600 nm and grown at 28°C. for 48 h. For fatty acid 
feeding experiments cultures were grown for 2.5 hs in YSM 
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containing 2% galactose followed by addition of 1% (w/v) 
Tergitol-40 and 250 uM of the appropriate fatty acid sub 
strate. Cells were harvested by centrifugation, washed twice 
with 0.1% NaHCO3, freeze-dried and used for fatty acid, 
TAG analysis and microsome isolation. 
Example 19 
Camelina Transformation and Selection 
0119 The binary vector containing a cassette for seed 
specific expression of Cpl DGAT1, Cpl DGAT1 trunc or Athl)- 
GAT1 was introduced into Agrobacterium tumefaciens by 
electroporation. Transgenic plants were generated by floral 
dip of Camelina wt plants (Lu and Kang, 2008, Plant Cell 
Reports, 27:273-8). Transgenic seeds among mature seeds 
were selected using DsRed marker and were also PCR con 
firmed. Expression of transgenes in developing seeds was 
confirmed by RT-PCR. 
Example 20 
TAG Quantification and FA Profiling 
0120 Total lipid extraction by Bligh Dyer: 30 mg of Cam 
elina seeds was weighed in glass test tubes, followed by 
addition of 270 ul (10 mg/ml) C17-TAG and 50 ul (1 mg/ml) 
C17-PC. Seeds were crushed in 3 ml methanol: chloroform 
(2:1 v/v) by grinding with a grinder and incubated for 1 h at 
room temperature with agitation. Extraction was continued 
by adding 1 ml of chloroform and 1.9 ml of water to a test tube 
and vortexed, centrifuged at 4000 rpm for 10 minutes. The 
organic (lower) phase was transferred to a new test tube, 400 
ul was saved for transesterification. The rest was used for 
separation of TAG, DAG and Polar lipids using Supelco Supel 
Clean LC-Si SPE (Sigma) columns. Dried total lipids were 
redissolved in 1 ml of heptane and loaded onto LC-Si SPE 
columns equilibrated according to manufacturer's guide 
lines, once the sample ran through the column first wax esters 
were eluted with 1.5 ml of 95:5 heptane: ethyl ether, second 
TAG fraction was eluted with 5 ml of heptane: ethyl ether 
80:20 (v/v). DAG was eluted with 3 ml chloroform: acetone 
80:20 (v/v). Columns were washed with 6 ml of acetone 
followed by elution of phospholipids with 5 ml methanol: 
chloroform: water 100:50:40 (v/v/v). Total phospholipids 
were pooled with addition of 1.33 ml chloroform and 1.31 ml 
water followed by vortexing and centrifugation at 4000 rpm 
for 10 minutes. The organic phase containing total phospho 
lipids was transferred into a new tube. 
0121 600 ul of polar lipid fraction was dried and transes 
terified the rest was redessolved in 100 ul chloroform and 
separated by TLC in a solvent system consisting of CHCl3: 
MeOH:H2O:30% ammonium hydroxide (65:35:3:2.5 V/v/v/ 
v). Bands from the TLC plates corresponding to PC were 
scraped onto wax paper and transferred to 13x100 mm test 
tubes. Transesterification of total lipids, TAG, and phospho 
lipid fractions was done in 1 ml of 2% sulphuric acid in 
methanol by heating at 90° C. for 30 min. Upon cooling the 
samples to room temperature 1 ml HO and 1 ml heptane was 
added followed by Vortexing and centrifuging. Heptane layer 
was transferred to GC vials and analyzed in GC.. 
Example 21 
Isolation of C. pulcherrima DGAT1 and DGAT2 
Genes 
0122 Potential genes identified as DGATs were blasted 
against A. thaliana gene database in TAIR BLAST 2.2.8. The 
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blast identified one gene model highly similar to A. thaliana 
DGAT1 thus named Cpl DGAT1. In addition three genes two 
of which are similar to R. communis, V. fordii DGAT2 were 
identified and designated as CpGAT2 A and Cpl DGAT2 C, 
the third one is similar to A. thaliana DGAT2 and was named 
CpDGAT2 B. The ORF of CpDGAT1 is 1482 bp encoding a 
484 amino acid polypeptide (Altschul et al., 1997, Nucl. 
Acids Res., 25:3389-402). Homology search blast analysis of 
484 deduced amino acid showed it being most identical, 59 
and 54%, to functionally characterized DGAT1s from A. 
thaliana and B. napus, respectively, while it shares ~39% 
identity with mammalian DGAT1S (FIG.11). The N terminus 
78 amino acids has no sequence homology in other known 
homologous DGAT1S (FIG. 12), the hydrophilic N-terminus 
of 151 and 80 residues in plants and animals, respectively, 
were found to be unique for every DGAT1. Nevertheless, the 
rest is highly conserved and identical to DGAT1s from plant 
species such as A. thaliana, B. napus, R. communis and O. 
sativa (FIG. 12). The SOSUI secondary structure prediction 
program predicted ten transmembrane regions in CpGAT1. 
Similarly 8-10 hydrophobic regions were identified in 
DGAT1s of different origins (Liu et al., 2012, Plant Biotech 
nol. J., 10:862-70). The average number of residues is higher 
for DGAT1s than that of DGAT2s corresponding to 20 kDa 
difference in molecular mass. Expression of Cpl DGAT1 in 
H1246 mutant, which contains disruptions of four acyltrans 
ferase genes that contribute to TAG synthesis, did not store 
TAG biosynthesis to the S. cerevisiae while Athl)GAT1 
expressing H1246 yeast cells make TAG. Expression of 
codon optimized CpGAT1 in H1246 yeast cells did not lead 
to any differences. Similarly, DGAT assay using radiola 
belled 10:0 and DAG 10:0/10:0 Substrates with microsomes 
from CpGAT1 expressing yeast cells did not result in for 
mation of TAG. 
Example 22 
Tissue-Specific Expression of C. pulcherrima 
DGATS 
(0123 Expression profile of CpDGAT1, CpDGAT2 A, 
CpGAT2 B and Cpl DGAT2 C in root, stem, leaf, flower 
and developing seeds of C. pulcherrima was analyzed (FIG. 
13). The transcript abundance of the genes was normalized to 
that of C. pulcherrima eukaryotic initiation factor and actin 
(CpelF4 and Cp Actin) genes. It was found that Cpl DGAT1 is 
specifically expressed in developing seeds. The three C. pull 
cherrima DGAT2 genes expression was observed in all tis 
sues, stronger expression of CpGAT2 A, Cpl DGAT2 B can 
be seen in developing seeds while Cpl DGAT2 C is expressed 
at similar levels in all tissues analyzed. 
Example 23 
Seed-Specific Expression of Cpl DGAT1 and 
CVLPAT2 Enhances Decanoic Acid and Caprylic 
Acid Content in Camelina sativa Seeds 
0.124 Cpl DGAT1 was expressed under seed specific gly 
cinin-1 promoter along with the C. viscosissima thioesterase 
(CvFatB1), known to be specific for C10:0, C12:0, C14:0 and 
C16:0 Acyl-ACP CvLPAT2 the ORF of 1155 bp was ampli 
fied from a cDNA prepared from total RNA from C. visco 
sissima from developing seeds. It was cloned into pBinG 
lyred vector under glycinin-1 promoter. 
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0.125 Analysis of seeds from T2 plants of 24 independent 
lines expressing CvFatB1+Cpl DGAT1 and CvPat31+CVL 
PAT2+Cpl DGAT1, as confirmed by reverse-transcription 
PCR, showed increased amounts of 10:0 (FIGS. 14 and 15). 
The 10:0 fatty acid levels in transgenic CvFatB1+CpGAT1 
and CvFatB1+CvLPAT2+CpDGAT1 T2 seeds reached as 
high as 13.5 and 21.5 mol% of TFA as compared to 8.0 mol 
% in lines expressing only CvFatB1, while that of C12:0. 
C14:0 and C16:0 stayed similar (FIGS. 14 and 15). Signifi 
cant decrease in the amounts of 18:2, 18:3 and 20:1 by 10, 18 
and 6 mol %, respectively, was seen in all CvFatB1+Cp)- 
GAT1 transgenic lines. The oil content in seeds from T3 
homozygous transgenic lines from CvFatB1+Cpl DGAT1 
(FIG. 14) and CvFatB1+CvLPAT2+CplDGAT1 (FIG. 15), 
which had the highest amounts of 10:0, was not significantly 
affected. In addition to C10:0, 3 to 5 mol % of C8:0 was 
detected in TAG in the seeds engineered to express CvFatB1+ 
CvLPAT2+CplDGAT1. 
Example 24 
Enhanced Amounts of C8:0 and C10:0 are Detected 
at Sn-2 Position of TAG from Seeds of Transgenic 
Camelina Lines Expressing CvLPAT2 or/and 
CplDGAT1 
0126 Stereospecific analysis of fatty acid species at sn-2 
position of TAG from engineered seeds was conducted to 
assess the efficiency of assembly of short and medium chain 
fatty acids in TAG. Fatty acid profile of sn-2 monoacylglyc 
erol obtained by digesting with TAG sn-1 and sn-3 specific 
lipase from Rhizomucor miehei (Sigma) revealed that while 
trace amounts of 10:0 is seen at sn-2 position of TAG from 
seeds of CvFatB1+CpGAT1 lines, there is a striking 
increase up to 20 mol% in CvFatB1+CvLPAT2 line and 33.1 
mol % in the relative content of 10:0 at Sn-2 of TAG from 
CvFatB1+CvLPAT2+CpDGAT1 line was observed (FIG. 
17). In addition to C10:0, 3 to 5 mol% of C8:0 was detected 
in TAG sn-2 position in the seeds engineered to express 
CvFatB1+CvLPAT2+CplDGAT1. 
0127. The increase of 10:0 at the sn-2 position of TAG 
from CvFatB1 expressing lines is accompanied by reduction 
of 18:2 and significantly that of 18:3 which is 17.4 mol % as 
compared to 44.3 mol % at this position in TAG from Wt 
camelina seeds. In C. pulcherrima fatty acid species at Sn-2 
position of TAG are 8:0 (up to 97 mol%) and C10:0 (3 mol%) 
while in C. viscosissima it is 12.6 mol% of C8:0 and 87.4 mol 
% of 10:0 (FIG. 17). 
Example 25 
DAG Species from C. sativa Transgenic Lines 
Overexpressing Cuphea Species Acyltransferases 
Contain Increased Amounts of Shorter Chain 
Saturated Fatty Acids 
0128 Fatty acid profile of DAG species from the trans 
genic lines was analyzed (FIG. 18). The data showed higher 
amounts of C10:0 and C16:0 fatty acids in lines expressing 
the Cuphea acyltransferases CVIPAT2 and Cpl DGAT1 in 
addition to the thioesterase, CvFatB1. The seeds of CvFatB1 
expressing lines contain ~4 mol % of C10:0, ~12 mol % of 
C16:0, while that of CvFatB1+CpDGAT1 and CvFatB1+ 
CvLPAT2 contain up to 8 mol% of C10:0, 3 mol% of C14:0 
and 20 mol % of C16:0. DAG species from CvFatB1+CvL 
PAT2+Cpl DGAT1 contain highest amount of C10:0 up to 14 
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mol%. The increase in the amounts of short and medium 
chain fatty acids in DAG species is accompanied by Substan 
tial decrease of 18:3. DAGs from developing seeds of C. 
viscosissima contain up to 12, 53, 8 and 32 mol % of C8:0, 
C10:0, C14:0 and C16:0, respectively. 
Example 26 
Accumulation of Short- and Medium-Chain Fatty 
Acids in Transgenic Camelina Lines Starts at 
Midstage in Developing Seeds 
I0129. Fatty acid composition of developing seeds from 
transgenic Camelina lines were analyzed at four stages after 
flowering: 10 DAF, 17 DAF, 22DAF and 30 DAF. Ten day 
developing seeds contain very low 10:0 (-2.5 mol %), main 
fatty acids are 16:0 (-14 mol %), 18:1 (20 mol %), 18:2 
(40-44 mol%), and 18:3 (18-20 mol%), the predominant one. 
The percent share of each fatty acid (C16:0 through 20:1) in 
TFA in transgenic lines is similar to that of wild type Cam 
elina plants. 17 day seeds produce more of shorter chain fatty 
acids 8:0 (4 mol %), 10:0 (up to 24 mol %), 12:0 (2.5-4 mol 
%), 14:0 (3 mol%) and higher amounts of 16:0 (13 mol%) in 
transgenic lines. In CvPat31+CvLpat2+Cpl DGAT1 the 
amount of 18:1 decreases, while 18:2, 18:3 and 20:1 make 15 
mol %, 16 mol % and 6 mol %, respectively, as compared to 
21.4, 30 and 12.7 mol % in wild type Camelina plants. 
0.130 22 day seeds produce more of short chain fatty acids 
5 mol % C8:0, 30 mol % 10:0, 7 mol % (12:0-14:0). The 
amounts of 16:0, 18:0, 18:1, 18:2, 18:3 and 20:1 in CvEatB1+ 
CvLPAT2+CpDGAT1 line are 12, 8, 12, 16, and 5 mol % as 
compared to 8, 13, 20, 41, and 10 mol% in seeds of wild type 
plants. Thus the share of 8:0 through 16:0 fatty acids total 
amount in this line reaches 54 mol % of TFA as compared to 
39 mol% in CvFatB1 line, 43% in CvFatB1+CpDGAT1 line 
and 8 mol % in wild type. 
I0131. In 30 days in seeds from CvFatB1 line there is 33.6 
mol % of 8:0-16:0, 22.4 mol%. 18:1, 13.7 mol%. 18:2, 16.0 
mol% 18:3 and 6.6 mol%20:1. CvFatB1+CpDGAT1 trans 
genic lines accumulate more 10:0, and 8:0-10:0 total fatty 
acids amount is 37.5 mol% while amounts of 18:1, 18:2, 18:3 
and 20:1 are similar to what is found in seeds from CvFatB1 
line. In CvFatB1+CvLPAT2+CpDGAT1 line the average 
share of 8:0-16:0 fatty acids is 43 mol% of TFA, 18.5 mol% 
being 10:0 and 13.2 mol % 18:1, 12.8 mol%. 18:2, 18.3 mol 
% 18:3, 6.3 mol%20:1. 
0.132. As seeds develop oil content increases in both wild 
type and transgenic Camelina lines. Major oil accumulation 
started in 17 days at which oil content doubled 26.5% as 
compared to 13% of dry weight in 10 days, followed by 
33.4% and 28%, after 22 and 30 days, respectively, in wild 
type. In CvFatB1+CVLPAT2+Cpl DGAT1 lines average oil 
content was 13%, 26%, 30% and 22.7%, as compared to 
thioesterase only expressing lines 11.8, 23.0, 24.6, and 
23.4%, in 10, 17, 22 and 30 days, respectively. 
Example 27 
CpDGAT1 has Preference for 10:0 Containing 
Substrates and Decanoyl CoA 
I0133) Substrate preferences of CpDGAT1 were tested 
using extracts from 22 day developing seeds of CvEATB1. 
CvFatB1+CpDGAT1, and CvFatB1+CvLPAT2+CpDGAT1 
(FIG. 20). Acyl-CoA dependent DGAT activity was exam 
ined by measuring the incorporation of ''C acyl-CoA into 
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DAG acceptors 10:0/10:0 (1,2-didecanoyl-sn-glycerol) or 
18:1/18:1 (1,2-dioleoyl-sn-glycerol). In seed extracts of 
CpGAT1 expressing lines TAG formation from 1,2-DAG 
10:0/10:0 and 10:0-CoA was enhanced. DGAT activity with 
1,2-DAG 10:0/10:0 and 10:0-CoA was similar 80.6+4.1 and 
63.6+23.4 pmol TAG/min/g protein in Wt and CvPat31 
expressing line, respectively. In CvPat31+Cpl DGAT1 and 
CvFatB1+CvLPAT2+CpDGAT1 lines the activity was 
346+77.5 and 323+57.9 pmol TAG/min/g protein, respec 
tively. 
Example 28 
Germination Efficiency of Short- and Medium-Chain 
Fatty Acid Rich Transgenic Camelina Seeds 
0134 High levels of short and medium chain fatty acids 
did not affect average seed weight observed for transgenic 
seeds obtained in greenhouse conditions (FIG. 20). The 
weight of 100 seeds from wild type Camelina was 79 mg, 74 
mg for CvFatB1,71 and 77 mg for CvFatB1+CpDGAT1, and 
CvFatB1+CvLPAT2+CpDGAT1 lines, respectively. 
0135 Germination efficiency of homozygous 10:0-16:0 
rich transgenic Camelina seeds was not significantly affected 
by high levels of 10:0 or increased amounts of 16:0 (FIG.22). 
Up to 93% of seeds from CvFatB1 line germinated in 10 days 
in greenhouse conditions, for CvFatB1+CpDGAT1 it was 
78% and 97% for CvFatB1+CvLPAT2+CplDGAT1, which 
contains highest amounts of short and medium chain fatty 
acids. 
Example 29 
Seed-Specific Expression of Cpl DGAT1 and 
CvLPAT2a Further Enhances Decanoic Acid Content 
in Camelina sativa Seeds 
0.136 Cpl DGAT1 was expressed under seed specific gly 
cinin-1 promoter along with the C. viscosissima thioesterase 
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(CvFatB1), known to be specific for C8:0 and C10:0 Acyl 
ACP. The CpuPAT2a ORF of 1164 bp was amplified from 
cDNA prepared from total RNA from C. pulcherrima devel 
oping seeds and was sub-cloned into pKMS3 vector under 
glycinin-1 promoters. A cassette comprising the glycinin-1 
promoter and CpulPAT2a gene was inserted into the pBinG 
lyRed-CvFatB1+CpDGAT1 to make the pBinGlyRed-Cv 
FatB1+CpuLPAT2a+CpDGAT1. 
0.137 Analysis of seeds from T2 lines expressing 
CvFatB1+CvLPAT2+CpDGAT1 and T3 lines expressing 
CvFatB1+CpuLPAT2a+CpDGAT1 showed increased 
amounts of 10:0 in TAG (FIGS. 16 and 24). The 10:0 fatty 
acid levels in transgenic CvFatB1+CvLPAT2a+CpGAT1 
T3 seeds reached as high as 18.5 and 27 mol% of TAGTFA 
as compared to 8.0 mol% in lines expressing only CVPat31, 
while that of C18:1, C18:2 and C18:3 stayed similar (FIGS. 
16 and 24). The oil content in seeds from T3 transgenic lines 
from CvFatB1+CvLPAT2a+CpDGAT1 (7,11), which had 
high amounts of 10:0, was not significantly affected (FIG. 
24A). The amount of C10:0 is even higher in seeds of Cam 
elina lines expressing CpulPAT2a in addition to CvFatB1 
and CpGAT1 (CvFatB1+CpulPAT2a+CpDGAT1). Fatty 
acid profile of Sn-2 monoacylglycerol obtained by digesting 
with TAG sn-1 and sn-3 specific lipase from Rhizomucor 
miehei (Sigma) indicated a significant increase in 10:0 at Sn-2 
position of TAG from seeds of both CvFatB1+CvLPAT2+ 
CplDGAT1 (FIG. 17) and CvFatB1+CpuLPAT2a+CplDGAT1 
(FIG. 24B) lines. It is notable also that 8:0 was detected in 
amounts of ~3 mol % in the total TAG and in the TAG sn-2 
position in seeds engineered to express CvFatB1+ 
CvLPAT2CpuLPAT2a+CplDGAT1. 
TABLE 1. 
Primers used for cloning CpDGAT1 and AthlGAT1 into yeast and 
Camelina expression vectors 
C. pulcherrima primers used for expression in yeast and 
Camelina 
CpDGAT1BamHIf CTAGGATCCAccATGgctCATGAGGCAGTCAG HisBamHI 
CpDGAT1AlaBamHIf CTAGGATCCAccATGgctCAGGCAGTCAGC BamHI 
CpDgat1trunc BamH1f GTCGGATCCAccATGGCTCACCGGACTTCA BamHI 
CpDGAT1Xballr ATATCTAGACTAGTCGATCCTTAATCCTC Xbar 
CpDGlnot1F ATAgcggcc.gcATGCATGAGGCAGTCAG BamH1 
TABLE 2 
Primers used for SQRT-PCR of Cp)GAT1, Cpl.)GAT2 A, Cp)GAT2 B, 
and CpGAT2 C 
Primer sequence 5'-3' Amplicon 
Gene name Primer name Forward Reverse size (bp) 
Cpl.)GAT1 SQCpDG1f CTTCAATCTCTGTATGGTCACTCTC 298 
SQCpDG1r GACATCAAGGCACAATCAAATCTC 
Cpl.)GAT2 A Cpl DGsqf GGAGATTCGCGAGGAGCTTAAGTAGG, 347 
Cpl DGsqr CATATGGAATGTCTCCTGCACACCAC 
Cpl.)GAT2 B CPDG2 2 sqF GAGCGAGATGCTGAGATTGTGTTCCT. 3O8 
CPDG2 2 sqR TCACTGTGCACCTCATTCACCTCTTC 
Cpl.)GAT2 C CpDG2 3hinsa F TGGTGTGCAGGAGACATTCTACATGGf 381 
ACTTGTGCCTTGTGTCGCTCGAATAG 
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Primers used for SQRT-PCR of Cpl.)GAT1, Cp)GAT2 A, Cpl.)GAT2 B, 
and CDDGAT2 C 
Primer sequence 5'-3' Amplicon 
Gene name Primer name Forward Reverse size (bp) 
Cp Actin CpACTf TTGCTTTGGACTACGAGCAGGAGAf 189 
CpACTr TGGAGTTGTAAGTCGTCTCGTGGA 
CeIF4 CpeIF4 RT F GGTGAAGCGTGACGAACTGAC 140 
CpeIF4 RT R |CTCTAGTGTTCTGGTCCATGTCTCC 
Cp)g1trF Not1 ATAgcggcc.gcATGGCTCACCGGACTTCA Not 
CpDg1R Not1 AATGCGGCCGCCTAGTCGATCCTTAAT Not 
Primers used for expression of CpDGAT2 genes in yeast 
Cpdg1 CTAGGATCCAccATGCGGGAGGAGACGAA BamHI 
Cpdg2 atatotagaTCAAAGGATTCTCAGTTTGA Xba 
Cpdg3 CTAGGATCCAccATGATAGGGTTCalATGA BamHI 
Cpdg4 atatotagaTCACAAAATTCTCAGTTCGA Xba 
Cpdg5 citaAAGCTTAccATGGGAGAGGAGGCGGAC HindIII 
Cpdgó atacticgagTTAAAGTATTCTCAGTTTGA XhoI 
A. thaliana DGAT1 primers used for cloning into yeast and Camelina transformation 
AthBanDGAT1F CTAGGATCCAccATGGCGATTTTGGATTC BamHI 
AthlxbaDGAT1R ATATCTAGATCATGACATCGATCCTTTTC Xba 
AthlNotif ATAgcggcc.gcATGGCGATTTTGGATT Notf 
Athnotr SEA Notr 
0138. It is to be understood that, while the methods and groups, etc. of these methods and compositions are disclosed. 
compositions of matter have been described herein in con junction with a number of different aspects, the foregoing 
description of the various aspects is intended to illustrate and 
not limit the Scope of the methods and compositions of matter. 
Other aspects, advantages, and modifications are within the 
Scope of the following claims. 
0139 Disclosed are methods and compositions that can be 
used for, can be used in conjunction with, can be used in 
preparation for, or are products of the disclosed methods and 
compositions. These and other materials are disclosed herein, 
and it is understood that combinations, Subsets, interactions, 
SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS : 16 
<21 Os SEQ ID NO 1 
&211s LENGTH: 1155 
&212s. TYPE: DNA 
<213> ORGANISM: Cuphea viscosissima 
<4 OOs SEQUENCE: 1 
That is, while specific reference to each various individual 
and collective combinations and permutations of these com 
positions and methods may not be explicitly disclosed, each is 
specifically contemplated and described herein. For example, 
if a particular composition of matter or a particular method is 
disclosed and discussed and a number of compositions or 
methods are discussed, each and every combination and per 
mutation of the compositions and the methods are specifically 
contemplated unless specifically indicated to the contrary. 
Likewise, any Subset or combination of these is also specifi 
cally contemplated and disclosed. 
atgg.cgattg cagoggcago tdtcatcttic ct citt.cggcc titat cittctt cqcctic cqgc 60 
ct cattatca at citct tcca gg.cgctittgc tittgtcc tta titcqgc citct tt cqaaaaac 12O 
gcc taccgga gaataalacag agtttittgca gaattgttgt titcggagct tt tatgccta 18O 
titcgattggit gggctggtgc taagctcaaa ttatttaccg accctgaaac ctitt cqccitt 24 O 
atgggcaagg aa catgctct ggit cataatt aat cacatga ctgaacttga Ctggatggitt 3 OO 
ggatgggitta tiggit cagca ttittggttgc Cttgggagca taat atctgt togaagaaa 360 
tdaacaaaat ttct tcc.ggit attggggtgg to aatgtggit titt cagagta cctatat citt 42O 
gagagaa.gct gggccaagga taaaagtaca ttaaagt cac at atcgagag gCtgatagac 48O 
taccc cctdc ccttctggitt gg taatttitt gtggaaggaa ct cqgtttac toggacaaaa 54 O 
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Ctcttggcag cccagcagta totgtct catctgggctac Cagtgcc.gag aaatgttittg 6OO 
atcc cacgta ctaagggittt tdttt catgt gtgagt caca togcgat catt togttc.ca.gca 660 
gtatatgatgtcacagtggc attcc ctaag actt cacctic caccaacgtt gctaaatctt 72 O 
titcgagggtc agt ccataat gct tcatgtt cacat caagc gacatgcaat gaaagattta 78O 
ccagaatc.cg atgatgcagt agcagagtgg ttagagaca aatttgttgga aaaggatgct 84 O 
ttgttggaca agcataatgc tigaggacact ttcagtggtc. aagaagttctg. t cataccggc 9 OO 
agcc.gc.cagt taaagttct ct tctggtggta at at Cttggg tttgtaac alacatttggg 96.O 
gctictaaagt t cctt Cagtg gtcat catgg aaggggaaag catttitcagc tat cqggctg 1 O2O 
ggcatcgt.ca citc tactitat gcacg tattg attctat cot cacaa.gcaga gcggit coaac 108 O 
Cctg.cggagg tecac aggc aaa.gctaaag accgggttgt Catctgaaa galaggtaacg 114 O 
gacaaggaaa act ag 1155 
<210s, SEQ ID NO 2 
&211s LENGTH: 384 
212. TYPE: PRT 
<213> ORGANISM: Cuphea viscosissima 
<4 OOs, SEQUENCE: 2 
Met Ala Ile Ala Ala Ala Ala Val Ile Phe Lieu. Phe Gly Lieu. Ile Phe 
1. 5 1O 15 
Phe Ala Ser Gly Lieu. Ile Ile Asn Lieu. Phe Glin Ala Lieu. Cys Phe Val 
2O 25 3O 
Lieu. Ile Arg Pro Lieu. Ser Lys Asn Ala Tyr Arg Arg Ile Asin Arg Val 
35 4 O 45 
Phe Ala Glu Lieu Lleu Lleu Ser Glu Lieu. Lieu. Cys Lieu. Phe Asp Trp Trp 
SO 55 6 O 
Ala Gly Ala Lys Lieu Lys Lieu. Phe Thr Asp Pro Glu Thir Phe Arg Lieu 
65 70 7s 8O 
Met Gly Lys Glu. His Ala Lieu Val Ile Ile Asn His Met Thr Glu Lieu. 
85 90 95 
Asp Trp Met Val Gly Trp Val Met Gly Gln His Phe Gly Cys Lieu. Gly 
1OO 105 11 O 
Ser Ile Ile Ser Val Ala Lys Llys Ser Thr Llys Phe Lieu Pro Val Lieu. 
115 12 O 125 
Gly Trp Ser Met Trp Phe Ser Glu Tyr Lieu. Tyr Lieu. Glu Arg Ser Trp 
13 O 135 14 O 
Ala Lys Asp Llys Ser Thr Lieu Lys Ser His Ile Glu Arg Lieu. Ile Asp 
145 150 155 160 
Tyr Pro Leu Pro Phe Trp Leu Val Ile Phe Val Glu Gly Thr Arg Phe 
1.65 17O 17s 
Thir Arg Thr Lys Lieu. Lieu Ala Ala Glin Glin Tyr Ala Val Ser Ser Gly 
18O 185 19 O 
Lieu Pro Val Pro Arg Asn Val Lieu. Ile Pro Arg Thr Lys Gly Phe Val 
195 2OO 2O5 
Ser Cys Val Ser His Met Arg Ser Phe Val Pro Ala Val Tyr Asp Val 
21 O 215 22O 
Thr Val Ala Phe Pro Llys Thr Ser Pro Pro Pro Thr Lieu. Lieu. Asn Lieu. 
225 23 O 235 24 O 
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Phe Glu Gly Glin Ser Ile Met Lieu. His Val His Ile Lys Arg His Ala 
245 250 255 
Met Lys Asp Lieu Pro Glu Ser Asp Asp Ala Val Ala Glu Trp Cys Arg 
26 O 265 27 O 
Asp Llys Phe Val Glu Lys Asp Ala Lieu. Lieu. Asp Llys His Asn Ala Glu 
27s 28O 285 
Asp Thr Phe Ser Gly Glin Glu Val Arg His Thr Gly Ser Arg Glin Leu 
29 O 295 3 OO 
Lys Ser Lieu. Leu Val Val Ile Ser Trp Val Val Val Thr Thr Phe Gly 
3. OS 310 315 32O 
Ala Lieu Lys Phe Lieu Gln Trp Ser Ser Trip Lys Gly Lys Ala Phe Ser 
3.25 330 335 
Ala Ile Gly Lieu. Gly Ile Val Thir Lieu. Lieu Met His Val Lieu. Ile Lieu 
34 O 345 35. O 
Ser Ser Glin Ala Glu Arg Ser Asn Pro Ala Glu Val Ala Glin Ala Lys 
355 360 365 
Lieu Lys Thr Gly Lieu. Ser Ile Ser Lys Llys Val Thr Asp Llys Glu Asn 
37 O 375 38O 
<210s, SEQ ID NO 3 
&211s LENGTH: 1164 
&212s. TYPE: DNA 
<213> ORGANISM: Cuphea avigera var. pulcherrima 
< 4 OO SEQUENCE: 3 
atgacgattig catcggcago tdtcgt.ctitt ctdtt cqgca ttct c ct citt cacct coggc 6 O 
ct cattatca atctottcca gg.cgttittgc tictdtcc titg tittggcct ct titcgaagaac 12 O 
gcct accqiga gaattaac cq agtttittgca gaatttittgc ccttggagtt tittatggcta 18O 
titccattggt giggctggtgc taagctcaaa ttatttaccg accctgaaac ctitt.cgc citt 24 O 
atgggcaagg alacatgct ct tt cataatt aat cacalaga ttgagcttga Ctggatggitt 3OO 
ggatgggttctgggtcagca tttaggttgc Cttgggagca tattatc.cgt togalagaaa 360 
t caacaaaat ttctt.ccggit ttittgggtgg to attatggit titt cagagta t ct attt citt 42O 
gagagaaact gggccalagga taaaaaaa.ca ttaaagt cac atatagagag gctgaaagat 48O 
tacic ccct gc cct tctggitt gataatttitt gtggaaggaa citcggitttac toggacaaaa 54 O 
Ctcttggcag cccagcagta totgcctica gctgggttac Cagtgcc.gag aaatgttittg 6OO 
atcc cacata ctaagggittt tdttt catct gtgagt caca togcgat catt togttc.cggca 660 
atatacgatgtcacggtggc attcc ctaag acttic acctic caccaacgat gctaaaactt 72 O 
titcgagggtc attic.cgtaga gct tcacgtt Cacat Caagc ggcatgcaat gaaagattta 78O 
ccagaatc.cg aagatgcagt agcacagtgg ttagagaca aatttgttga gaaggatgct 84 O 
ttgttggaca agcataatgc tigaggacact ttcagtggtc. aagaagttca t catgtcggc 9 OO 
cgc.ccgataa agt ctottct ggtggtaata t cqtgggtgg ttgtaataat atttggggct 96.O 
ctaaagttcc titcagtgg to at cact citta t catcatgga aggggaaagc attitt cagtt 1 O2O 
atcgggttgg gcactgtc.gc act act catg caaat attga ttctatoctic acaag cagag 108 O 
cggit ct at CC Ctgccaagga gacaccggca aatctaaaga ccgagttgtc. gtcCtcaaag 114 O 
alaggtaacga acaaggaaaa ctag 1164. 
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<210s, SEQ ID NO 4 
&211s LENGTH: 387 
212. TYPE: PRT 
<213> ORGANISM: Cuphea avigera var. pulcherrima 
<4 OOs, SEQUENCE: 4 
Met Thr Ile Ala Ser Ala Ala Val Val Phe Leu Phe Gly Ile Leu Lieu. 
1. 5 1O 15 
Phe Thir Ser Gly Lieu. Ile Ile Asn Lieu Phe Glin Ala Phe Cys Ser Val 
2O 25 3O 
Lieu Val Trp Pro Lieu. Ser Lys Asn Ala Tyr Arg Arg Ile Asin Arg Val 
35 4 O 45 
Phe Ala Glu Phe Lieu Pro Leu Glu Phe Leu Trp Leu Phe His Trp Trp 
SO 55 6 O 
Ala Gly Ala Lys Lieu Lys Lieu. Phe Thr Asp Pro Glu Thir Phe Arg Lieu 
65 70 7s 8O 
Met Gly Lys Glu. His Ala Lieu Val Ile Ile Asn His Lys Ile Glu Lieu. 
85 90 95 
Asp Trp Met Val Gly Trp Val Lieu. Gly Glin His Lieu. Gly Cys Lieu. Gly 
1OO 105 11 O 
Ser Ile Leu Ser Val Ala Lys Llys Ser Thr Llys Phe Leu Pro Val Phe 
115 12 O 125 
Gly Trp Ser Leu Trp Phe Ser Glu Tyr Lieu. Phe Lieu. Glu Arg Asn Trp 
13 O 135 14 O 
Ala Lys Asp Llys Llys Thr Lieu Lys Ser His Ile Glu Arg Lieu Lys Asp 
145 150 155 160 
Tyr Pro Leu Pro Phe Trp Lieu. Ile Ile Phe Val Glu Gly Thr Arg Phe 
1.65 17O 17s 
Thir Arg Thr Lys Lieu. Lieu Ala Ala Glin Glin Tyr Ala Ala Ser Ala Gly 
18O 185 19 O 
Lieu Pro Val Pro Arg Asn Val Lieu. Ile Pro His Thr Lys Gly Phe Val 
195 2OO 2O5 
Ser Ser Val Ser His Met Arg Ser Phe Val Pro Ala Ile Tyr Asp Val 
21 O 215 22O 
Thr Val Ala Phe Pro Llys Thr Ser Pro Pro Pro Thr Met Leu Lys Lieu. 
225 23 O 235 24 O 
Phe Glu Gly. His Ser Val Glu Lieu. His Val His Ile Lys Arg His Ala 
245 250 255 
Met Lys Asp Lieu Pro Glu Ser Glu Asp Ala Val Ala Glin Trp Cys Arg 
26 O 265 27 O 
Asp Llys Phe Val Glu Lys Asp Ala Lieu. Lieu. Asp Llys His Asn Ala Glu 
27s 28O 285 
Asp Thr Phe Ser Gly Glin Glu Val His His Val Gly Arg Pro Ile Llys 
29 O 295 3 OO 
Ser Lieu. Leu Val Val Ile Ser Trp Val Val Val Ile Ile Phe Gly Ala 
3. OS 310 315 32O 
Lieu Lys Phe Lieu. Glin Trp Ser Ser Lieu. Lieu. Ser Ser Trp Llys Gly Lys 
3.25 330 335 
Ala Phe Ser Val Ile Gly Lieu. Gly. Thr Val Ala Lieu Lleu Met Glin Ile 
34 O 345 35. O 
Lieu. Ile Lieu. Ser Ser Glin Ala Glu Arg Ser Ile Pro Ala Lys Glu Thir 
355 360 365 
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115 12 O 125 
Asn Glu Arg Ala Ile Tyr Ile Cys Asn His Ala Ser Pro Lieu. Asp Ile 
13 O 135 14 O 
Val Lieu. Thir Met Trp Lieu. Thr Pro Lys Gly Thr Val Cys Ile Ala Lys 
145 150 155 160 
Lys Glu Ile Val Trp Tyr Pro Lieu. Ile Gly Glin Lieu. Tyr Ala Lieu Ala 
1.65 17O 17s 
Gly His Lieu. Arg Ile Asp Arg Ser Asn Pro Val Ala Ala Ile Glin Ser 
18O 185 19 O 
Met Lys Glu Val Ala Arg Ala Val Val Lys Asn Asp Lieu. Ser Lieu. Ile 
195 2OO 2O5 
Ile Phe Pro Glu Gly Thr Arg Ser Lys Asp Gly Arg Lieu. Lieu Pro Phe 
21 O 215 22O 
Llys Lys Gly Phe Val His Lieu Ala Lieu. Glin Thr Arg Arg Pro Ile Val 
225 23 O 235 24 O 
Pro Ile Val Lieu. Thr Gly Thr His Met Ala Trp Arg Lys Gly Ser Lieu. 
245 250 255 
His Ile Arg Pro Thr Pro Leu. Thr Val Lys Tyr Lieu Pro Pro Ile Val 
26 O 265 27 O 
Thir Thr Asp Trp Thr Pro Asp Arg Val Glu Asp Tyr Thr Lys Met Ile 
27s 28O 285 
His Asp Ile Tyr Val Asn His Lieu Pro Glu Ser Glin Gln Pro Lieu. Arg 
29 O 295 3 OO 
Pro Lys Glu Ser 
3. OS 
<210s, SEQ ID NO 7 
&211s LENGTH: 1482 
&212s. TYPE: DNA 
<213> ORGANISM: Cuphea avigera var. pulcherrima 
<4 OO > SEQUENCE: 7 
atgcatgagg cagt cago catttitcticcac cqccacgc.cc cactic totct citc.cggcttic 6 O 
gccatgg.cga t cqtcagogg cactic toggc gtc.gcagcct cotcc tt cat ccc.cgacticc 12 O 
gat cacticca ccacct ct co ttct citcc.gc aagcdcaact cotct tcact ttitt.cccaag 18O 
gcct cagaca cittcttctgt cqacggcaag gocgct cacc ggactitcatc. tcc.ggttcac 24 O 
ttgaaactgg cagagagt cc tict cagotcg agaaat atct tcaag cagala t catgaaggt 3OO 
citct tcaatc. tctgtatggit cact citcgtt gctgtcatca toccact citt cotcgagaat 360 
CtcCtcaagt atggttggct aatgaagaga gacttittggit tagtacgtt Cacagcctgg 42O 
cc.gct citt catttgtagcct cqgtc.ttic cc attitt coccc ttgcago att cqtagt cdag 48O 
aagttggc cc agaagaatct tctg.ccggaa ccgattgttt tatgttctica tdt cattatc 54 O 
actitcggcat cogtcc titta t ccc.gcactt gtaattctga gatttgattg togccttgatg 6OO 
tctggitat cq gtctgatgct c tatt cittgc gct ctittggit taaaattggit gtc.ctatgcg 660 
Cacacaagtt acgatatgag atgtgaggcc aagttct catc ttgagggaala aagtagtgcg 72 O 
gattcaaaaa atggagagct tcc ttaccgc gtaaa.catca aagat cittgc gtact tcatg 78O 
gttgcaccga ccctatgtta cca.gctitt cq tat cotcgca cacaattitat acgtaaattit 84 O 
tgggtggctic gccaagttctt gaagttgata ttggt caatig tagtaatggg attcatCatt 9 OO 
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gaacaatata tatt ccc.gt tatgcataac totaaac ccc cacggcgggg at attggitta 96.O 
cattt catcg agagaaattt gaagcttgcg gttcCaagta taggcctgtg gttittgcata O2O 
ttct actic catttitt catct ctdgctgaat at agtggcgg agctic ct cog titttgg.cgat O8O 
cgtgaattitt ataaagattg gtggaatgcc aagaatatgg aggagtact.g. galagatgtgg 14 O 
alacatacctg. t t cataggtg gatggttcga catttatacg gtcCttgcat galagagaaaa 2OO 
ttac.cgaggt giggit cqcg at ttctatot catttct cittgt ctdcagtgtt gcatgagat c 26 O 
tgtgtaagtg titc catgc.ca ttgttcCag Ctttgggcat t caacggaat gatgctt cag 32O 
attic.cgctgg tttgagttc gaalaccctta caaaagaggit toccaagctic taaggctggg 38O 
aatgtatt ct tctggttctt gttttgtatic tatggc.cago ctaattgttgt gct tatgtac 44 O 
taccacgc.ct tatggaacg gagaggatta aggat.cgact ag 482 
<210s, SEQ ID NO 8 
&211s LENGTH: 493 
212. TYPE: PRT 
<213> ORGANISM: Cuphea avigera var. pulcherrima 
<4 OOs, SEQUENCE: 8 
Met His Glu Ala Val Ser His Phe Lieu. His Arg His Ala Pro Leu Ser 
1. 5 1O 15 
Lieu. Ser Gly Phe Ala Met Ala Ile Val Ser Gly Thr Lieu. Gly Val Ala 
2O 25 3O 
Ala Ser Ser Phe Ile Pro Asp Ser Asp His Ser Thr Thr Ser Pro Ser 
35 4 O 45 
Lieu. Arg Lys Arg Asn. Ser Ser Ser Lieu. Phe Pro Lys Ala Ser Asp Thr 
SO 55 6 O 
Ser Ser Val Asp Gly Lys Ala Ala His Arg Thir Ser Ser Pro Val His 
65 70 7s 8O 
Lieu Lys Lieu Ala Glu Ser Pro Lieu. Ser Ser Arg Asn. Ile Phe Lys Glin 
85 90 95 
Asn His Glu Gly Lieu. Phe Asn Lieu. Cys Met Val Thir Lieu Val Ala Val 
1OO 105 11 O 
Ile Ile Arg Lieu. Phe Lieu. Glu Asn Lieu. Lieu Lys Tyr Gly Trp Lieu Met 
115 12 O 125 
Lys Arg Asp Phe Trp Leu Ser Thr Phe Thr Ala Trp Pro Leu Phe Ile 
13 O 135 14 O 
Cys Ser Leu Gly Lieu Pro Ile Phe Pro Leu Ala Ala Phe Val Val Glu 
145 150 155 160 
Llys Lieu Ala Glin Lys Asn Lieu. Lieu Pro Glu Pro Ile Val Lieu. Cys Ser 
1.65 17O 17s 
His Val Ile Ile Thr Ser Ala Ser Val Lieu. Tyr Pro Ala Leu Val Ile 
18O 185 19 O 
Lieu. Arg Phe Asp Cys Ala Lieu Met Ser Gly Ile Gly Lieu Met Lieu. Tyr 
195 2OO 2O5 
Ser Cys Ala Leu Trp Leu Lys Lieu Val Ser Tyr Ala His Thr Ser Tyr 
21 O 215 22O 
Asp Met Arg Cys Glu Ala Lys Ser Arg Lieu. Glu Gly Llys Ser Ser Ala 
225 23 O 235 24 O 
Asp Ser Lys Asn Gly Glu Lieu Pro Tyr Arg Val Asn. Ile Lys Asp Lieu 
245 250 255 
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Ala Tyr Phe Met Val Ala Pro Thr Lieu. Cys Tyr Gln Leu Ser Tyr Pro 
26 O 265 27 O 
Arg Thr Glin Phe Ile Arg Llys Phe Trp Val Ala Arg Glin Val Lieu Lys 
27s 28O 285 
Lieu. Ile Leu Val Asn Val Val Met Gly Phe Ile Ile Glu Glin Tyr Met 
29 O 295 3 OO 
Ile Pro Val Met His Asn Ser Llys Pro Pro Arg Arg Gly Tyr Trp Leu 
3. OS 310 315 32O 
His Phe Ile Glu Arg Asn Lieu Lys Lieu Ala Val Pro Ser Ile Gly Lieu. 
3.25 330 335 
Trp Phe Cys Ile Phe Tyr Ser Ile Phe His Leu Trp Lieu. Asn Ile Val 
34 O 345 35. O 
Ala Glu Lieu. Lieu. Arg Phe Gly Asp Arg Glu Phe Tyr Lys Asp Trp Trip 
355 360 365 
Asn Ala Lys Asn Met Glu Glu Tyr Trp Llys Met Trp Asn. Ile Pro Val 
37 O 375 38O 
His Arg Trp Met Val Arg His Lieu. Tyr Gly Pro Cys Met Lys Arg Llys 
385 390 395 4 OO 
Lieu Pro Arg Trp Val Ala Ile Ser Ile Ser Phe Lieu Lleu Ser Ala Val 
4 OS 41O 415 
Lieu. His Glu Ile Cys Val Ser Val Pro Cys His Val Phe Glin Leu Trp 
42O 425 43 O 
Ala Phe ASn Gly Met Met Lieu. Glin Ile Pro Leu Val Lieu Ser Ser Lys 
435 44 O 445 
Pro Leu Gln Lys Arg Phe Pro Ser Ser Lys Ala Gly Asn Val Phe Phe 
450 45.5 460 
Trp Phe Leu Phe Cys Ile Tyr Gly Glin Pro Asn Cys Val Leu Met Tyr 
465 470 47s 48O 
Tyr His Ala Lieu Met Glu Arg Arg Gly Lieu. Arg Ile Asp 
485 490 
<210s, SEQ ID NO 9 
&211s LENGTH: 1419 
&212s. TYPE: DNA 
<213> ORGANISM: Cuphea viscosissima 
<4 OOs, SEQUENCE: 9 
atggcgat.cg ttggcgt.cga cqctt cotcc ct cagtc.ccg act ct ct cog cc.ggcgcaac 6 O 
titcgaccalag Ctt cactict c ticc calagacic accggcggca gtgttgtcga tigacgctgat 12 O 
aacttgaagc tiggagcgcga cqC caagaaa got caccgga Ctt Catct cc ggtacactgg 18O 
aagttggctg agagtic ct ct cagct coacc aatat citt.ca agcagagtica togcaggit ct c 24 O 
ttaa acct cit gcatggtcgt tottattgct gtcaa.ca.gcc gact catcct cqagaat ct c 3OO 
atcaagtatg gttggct cat galagaggaac ttittggttgc atacgtttac agactggcct 360 
citct tcatgt gtagcc ttgg tott.cccatt titc cct cittg cagcatt cot agt cdagaag 42O 
ttggcgcago ggaatcgttt gcc tdaacct attgt attitt gttct catgt cattat cact 48O 
acggcatc.cg toctittatcc cqc acttgta attctgggat citgattctgc cittgat citct 54 O 
gg tattgttctgatgct cat togcttgcact ctittggittaa aattggtgtc. atatgcgcac 6OO 
acaagttacg atatgagatg taggccaag tict Cttcttg aggga caatic tagtgctgct 660 
tcaaaaaatg tagagcttico ttaccg.cgta aacttcaaag atc.ttgttgta titt catggitt 72 O 
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gcacccaccc tatgttacca gattt coitat cotcgcacac aatgtgtacg taaaggttgg 78O 
gttgct cqcg aagttcttgaa gttgatattgttcaatggag taatgggatt cat cattgaa 84 O 
caatatatga titcctic titat gcatalactict aaaggcc cac agaggggaga ttggitta cat 9 OO 
ttcatcgaaa gogattittgaa gottgcggitt coaggcgitat acctgtggitt ttgcatatt c 96.O 
tactgcattt ttcatctotg gttgaatata citggcagagc ticcitatgttt tdgcgatcqt 1 O2O 
gaattittata gagactggtg gaatgccaag alacatggagg agtactggala gatgtggaac 108 O 
atacctgttc ataagtggat ggtgcggc at ttatacggtc. cct gcttgaa gaggaaaata 114 O 
cc.gagg togg togcaatttic tat ct cattt citcttgtctg cagtgttgca tdagct tatt 12 OO 
gtcagtatt c catgccatgt gttcatgctg tdggcattca citggaatgat actitcagatt 126 O 
cc.gctggttt tagttctgaa accCttacaa aaaatgttcc agagctc.cgt ggctgggaat 132O 
atgttcttct ggttcttctt ttgcatctitt ggc.ca.gc.cca totgttgtgct tatgtactac 1380 
Catgcc atga tiggat.cgtaa aatat cacag accgactag 1419 
<210s, SEQ ID NO 10 
&211s LENGTH: 472 
212. TYPE: PRT 
<213> ORGANISM: Cuphea viscosissima 
<4 OOs, SEQUENCE: 10 
Met Ala Ile Val Gly Val Asp Ala Ser Ser Lieu Ser Pro Asp Ser Lieu 
1. 5 1O 15 
Arg Arg Arg Asn. Phe Asp Glin Ala Ser Lieu. Ser Pro Llys Thir Thr Gly 
2O 25 3O 
Gly Ser Val Val Asp Asp Ala Asp Asn Lieu Lys Lieu. Glu Arg Asp Ala 
35 4 O 45 
Llys Lys Ala His Arg Thr Ser Ser Pro Wal His Trp Llys Lieu Ala Glu 
SO 55 6 O 
Ser Pro Leu Ser Ser Thr Asn Ile Phe Lys Glin Ser His Ala Gly Lieu. 
65 70 7s 8O 
Lieu. Asn Lieu. Cys Met Val Val Lieu. Ile Ala Val Asn. Ser Arg Lieu. Ile 
85 90 95 
Lieu. Glu Asn Lieu. Ile Llys Tyr Gly Trp Lieu Met Lys Arg Asn. Phe Trp 
1OO 105 11 O 
Lieu. His Thr Phe Thr Asp Trp Pro Leu Phe Met Cys Ser Leu Gly Lieu. 
115 12 O 125 
Pro Ile Phe Pro Lieu Ala Ala Phe Lieu Val Glu Lys Lieu Ala Glin Arg 
13 O 135 14 O 
Asn Arg Lieu Pro Glu Pro Ile Val Phe Cys Ser His Val Ile Ile Thr 
145 150 155 160 
Thir Ala Ser Val Lieu. Tyr Pro Ala Lieu Val Ile Lieu. Gly Ser Asp Ser 
1.65 17O 17s 
Ala Lieu. Ile Ser Gly Ile Val Lieu Met Lieu. Ile Ala Cys Thr Lieu. Trip 
18O 185 19 O 
Lieu Lys Lieu Val Ser Tyr Ala His Thir Ser Tyr Asp Met Arg Cys Glu 
195 2OO 2O5 
Ala Lys Ser Lieu. Lieu. Glu Gly Glin Ser Ser Ala Ala Ser Lys Asn Val 
21 O 215 22O 
Glu Lieu Pro Tyr Arg Val Asn Phe Lys Asp Leu Val Tyr Phe Met Val 
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225 23 O 235 24 O 
Ala Pro Thr Lieu. Cys Tyr Glin Ile Ser Tyr Pro Arg Thr Glin Cys Val 
245 250 255 
Arg Lys Gly Trp Val Ala Arg Glu Val Lieu Lys Lieu. Ile Lieu. Phe Asn 
26 O 265 27 O 
Gly Val Met Gly Phe Ile Ile Glu Gln Tyr Met Ile Pro Leu Met His 
27s 28O 285 
Asn Ser Lys Gly Pro Glin Arg Gly Asp Trp Lieu. His Phe Ile Glu Arg 
29 O 295 3 OO 
Ile Leu Lys Lieu Ala Val Pro Gly Val Tyr Lieu. Trp Phe Cys Ile Phe 
3. OS 310 315 32O 
Tyr Cys Ile Phe His Lieu. Trp Lieu. Asn. Ile Lieu Ala Glu Lieu. Lieu. Cys 
3.25 330 335 
Phe Gly Asp Arg Glu Phe Tyr Arg Asp Trp Trp Asn Ala Lys Asn Met 
34 O 345 35. O 
Glu Glu Tyr Trp Llys Met Trp Asn Ile Pro Val His Lys Trp Met Val 
355 360 365 
Arg His Lieu. Tyr Gly Pro Cys Lieu Lys Arg Lys Ile Pro Arg Ser Val 
37 O 375 38O 
Ala Ile Ser Ile Ser Phe Lieu. Lieu. Ser Ala Val Lieu. His Glu Lieu. Ile 
385 390 395 4 OO 
Val Ser Ile Pro Cys His Val Phe Met Leu Trp Ala Phe Thr Gly Met 
405 410 415 
Ile Lieu. Glin Ile Pro Lieu Val Lieu. Ser Ser Llys Pro Lieu Gln Lys Met 
42O 425 43 O 
Phe Glin Ser Ser Val Ala Gly Asn Met Phe Phe Trp Phe Phe Phe Cys 
435 44 O 445 
Ile Phe Gly Glin Pro Met Cys Val Lieu Met Tyr Tyr His Ala Met Met 
450 45.5 460 
Asp Arg Lys Ile Ser Glin Thr Asp 
465 470 
<210s, SEQ ID NO 11 
&211s LENGTH: 126 O 
&212s. TYPE: DNA 
<213> ORGANISM: Cuphea viscosissima 
<4 OOs, SEQUENCE: 11 
atggtggctg ctgcagdaac ttctgcattc titcc.ccgttc cagc.cccggg aacct cocct 6 O 
aaac ccggga agt ccggcaa citggc catcg agcttgagcc ctaccttcaa gcc caagttca 12 O 
atc.cccaatg gcggattt Caggitta aggca aatgc.ca.gtg cc catcc tala ggctaacggit 18O 
tctgcagtaa atctaaagtic toggcagocto aac acticagg aggacacttic gtcgt.ccc.ct 24 O 
cctic ccc.ggg ctitt cottaa ccagttgcct gattggagta togcttctgac togcaat cacg 3OO 
accgt.ctt.cg tdgcggcaga galagcagtgg accatgcttgataggaaatc taagaggcct 360 
gacatgctic tigact cqgt tigttgaag agt attgttc gagatgggct cqtgtcCaga 42O 
cacagtttitt cqattagatc titatgaaata gg.cgctgatc gaacago: ct c tatagagacg 48O 
citgatgaacc acttgcagga aacaactato aat cattgta agagtttggg tott cataat 54 O 
gacggCtttg gtcgtact co togatgtgt aaaaacgacc ticatttgggit gct tacaaaa 6OO 
atgcagat.ca tdtgaatcg ct accCaact toggtgata ctgttgagat Caatacctgg 660 
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ttct ct cagt cqgggaaaat cqg tatggct agcgattggc taataagtga ttgcaacaca 72 O 
ggagaaattic titataagagc aacgagcgtg tdggctatga tigaatcaaaa gacgagalaga 78O 
ttct caagac titc catacga gottcgc.cag gagittaacac ct cattttgt gigact ct cot 84 O 
Catgtcattg aagacaatga t cagalaattig cqtaagtttg atgtgaagac tdgtgatt CC 9 OO 
attcgcaagg gtctaact co gaggtggaat gaCttggatg taat cagca cqtaa.gcaac 96.O 
gtgaagtaca ttgggtggat t ct cagagt atgcc-aatag aagttittgga gacccaggag 1 O2O 
Ctatgct Ctc. tcaccgttga atataggcgg gaatgcggala tigacagtgt gctggagt cc 108 O 
gtgactgctg tdgatcCctic agaaaatgga ggc.cggit ct c agtacaa.gca cct tctg.cgg 114 O 
Cttgaggatg ggactgat at C9tgaagagt agaactgagt ggcgaccgala gaatgcagga 12 OO 
actaacgggg catat caac at Caacagca aagacittcaa atggaaactic ggt ct ct tag 126 O 
<210s, SEQ ID NO 12 
&211s LENGTH: 419 
212. TYPE: PRT 
<213> ORGANISM: Cuphea viscosissima 
<4 OOs, SEQUENCE: 12 
Met Wall Ala Ala Ala Ala Thir Ser Ala Phe Phe Pro Wall Pro Ala Pro 
1. 5 1O 15 
Gly. Thir Ser Pro Llys Pro Gly Lys Ser Gly Asn Trp Pro Ser Ser Lieu. 
2O 25 30 
Ser Pro Thr Phe Llys Pro Llys Ser Ile Pro Asn Gly Gly Phe Glin Val 
35 4 O 45 
Lys Ala Asn Ala Ser Ala His Pro Lys Ala Asn Gly Ser Ala Val Asn 
SO 55 6 O 
Lieu Lys Ser Gly Ser Lieu. Asn Thr Glin Glu Asp Thr Ser Ser Ser Pro 
65 70 7s 8O 
Pro Pro Arg Ala Phe Lieu. Asn Glin Lieu Pro Asp Trp Ser Met Lieu. Lieu. 
85 90 95 
Thr Ala Ile Thr Thr Val Phe Val Ala Ala Glu Lys Gln Trp Thr Met 
1OO 105 11 O 
Lieu. Asp Arg Llys Ser Lys Arg Pro Asp Met Lieu Val Asp Ser Val Gly 
115 12 O 125 
Lieu Lys Ser Ile Val Arg Asp Gly Lieu Val Ser Arg His Ser Phe Ser 
13 O 135 14 O 
Ile Arg Ser Tyr Glu Ile Gly Ala Asp Arg Thr Ala Ser Ile Glu Thr 
145 150 155 160 
Lieu Met Asn His Lieu. Glin Glu Thir Thr Ile Asn His Cys Llys Ser Lieu. 
1.65 17O 17s 
Gly Lieu. His Asn Asp Gly Phe Gly Arg Thr Pro Gly Met Cys Lys Asn 
18O 185 19 O 
Asp Lieu. Ile Trp Val Lieu. Thir Lys Met Glin Ile Met Val Asn Arg Tyr 
195 2OO 2O5 
Pro Thir Trp Gly Asp Thr Val Glu Ile Asn. Thir Trp Phe Ser Glin Ser 
21 O 215 22O 
Gly Lys Ile Gly Met Ala Ser Asp Trp Lieu. Ile Ser Asp Cys Asn. Thir 
225 23 O 235 24 O 
Gly Glu Ile Lieu. Ile Arg Ala Thir Ser Val Trp Ala Met Met Asn Glin 
245 250 255 
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gctatggat.c cct caaaagt tagt cc.gt tot cagtacc agc acct tct gcggcttgag 114 O 
gatgggactg. Ctatcgtgaa cigtgcaact gagtggcggc cqaagaatgc aggagctaac 12 OO 
gggg.cgat at Caacgggaaa gacttcaaat ggaaact cqg tct Cttag 1248 
<210s, SEQ ID NO 14 
&211s LENGTH: 415 
212. TYPE: PRT 
<213> ORGANISM: Cuphea hookeriana 
<4 OOs, SEQUENCE: 14 
Met Wall Ala Ala Ala Ala Ser Ser Ala Phe Phe Pro Wall Pro Ala Pro 
1. 5 1O 15 
Gly Ala Ser Pro Llys Pro Gly Llys Phe Gly Asn Trp Pro Ser Ser Lieu. 
2O 25 3O 
Ser Pro Ser Phe Llys Pro Llys Ser Ile Pro Asn Gly Gly Phe Glin Val 
35 4 O 45 
Lys Ala Asn Asp Ser Ala His Pro Lys Ala Asn Gly Ser Ala Val Ser 
SO 55 6 O 
Lieu Lys Ser Gly Ser Lieu. Asn Thr Glin Glu Asp Thr Ser Ser Ser Pro 
65 70 7s 8O 
Pro Pro Arg Thr Phe Lieu. His Glin Lieu Pro Asp Trp Ser Arg Lieu. Lieu. 
85 90 95 
Thr Ala Ile Thir Thr Val Phe Val Llys Ser Lys Arg Pro Asp Met His 
1OO 105 11 O 
Asp Arg Llys Ser Lys Arg Pro Asp Met Lieu Val Asp Ser Phe Gly Lieu 
115 12 O 125 
Glu Ser Thr Val Glin Asp Gly Lieu Val Phe Arg Glin Ser Phe Ser Ile 
13 O 135 14 O 
Arg Ser Tyr Glu Ile Gly Thr Asp Arg Thr Ala Ser Ile Glu Thir Lieu 
145 150 155 160 
Met Asn His Leu Gln Glu Thir Ser Lieu. Asn His Cys Lys Ser Thr Gly 
1.65 17O 17s 
Ile Lieu. Lieu. Asp Gly Phe Gly Arg Thr Lieu. Glu Met Cys Lys Arg Asp 
18O 185 19 O 
Lieu. Ile Trp Val Val Ile Llys Met Glin Ile Llys Val Asn Arg Tyr Pro 
195 2OO 2O5 
Ala Trp Gly Asp Thr Val Glu Ile Asn. Thir Arg Phe Ser Arg Lieu. Gly 
21 O 215 22O 
Lys Ile Gly Met Gly Arg Asp Trp Lieu. Ile Ser Asp Cys Asn Thr Gly 
225 23 O 235 24 O 
Glu Ile Lieu Val Arg Ala Thir Ser Ala Tyr Ala Met Met Asin Gln Lys 
245 250 255 
Thir Arg Arg Lieu. Ser Llys Lieu Pro Tyr Glu Val His Glin Glu Ile Val 
26 O 265 27 O 
Pro Lieu. Phe Val Asp Ser Pro Val Ile Glu Asp Ser Asp Lieu Lys Val 
27s 28O 285 
His Llys Phe Llys Val Llys Thr Gly Asp Ser Ile Glin Lys Gly Lieu. Thir 
29 O 295 3 OO 
Pro Gly Trp Asn Asp Lieu. Asp Wall Asn Gln His Val Ser Asn. Wall Lys 
3. OS 310 315 32O 
Tyr Ile Gly Trp Ile Lieu. Glu Ser Met Pro Thr Glu Val Lieu. Glu Thr 
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1. 5 1O 15 
Val Thr Ser Ser Arg Pro Gly Llys Pro Gly Asn Gly Ser Ser Ser Phe 
2O 25 3O 
Ser Pro Ile Llys Pro Llys Phe Val Ala Asn Gly Gly Lieu. Glin Val Lys 
35 4 O 45 
Ala Asn Ala Ser Ala Pro Pro Lys Ile Asin Gly Ser Ser Val Gly Lieu 
SO 55 6 O 
Lys Ser Cys Ser Lieu Lys Thr Glin Glu Asp Thr Pro Ser Ala Pro Ala 
65 70 7s 8O 
Pro Arg Thr Phe Ile Asn Gln Lieu Pro Asp Trp Ser Met Lieu. Lieu Ala 
85 90 95 
Ala Ile Thir Thr Ala Phe Lieu Ala Ala Glu Lys Gln Trp Met Met Lieu 
1OO 105 11 O 
Asp Trp Llys Pro Lys Arg Pro Asp Met Lieu Val Asp Pro Phe Gly Lieu 
115 12 O 125 
Gly Ser Ile Val Gln His Gly Lieu Val Phe Arg Glin Asn Phe Ser Ile 
13 O 135 14 O 
Arg Ser Tyr Glu Ile Gly Ala Asp Arg Thr Ala Ser Ile Glu Thr Val 
145 150 155 160 
Met Asn His Lieu. Glin Glu Thir Ala Lieu. Asn His Val Llys Ser Ala Gly 
1.65 17O 17s 
Lieu Met Asn Asp Gly Phe Gly Arg Thr Pro Glu Met Tyr Lys Lys Asp 
18O 185 19 O 
Lieu. Ile Trp Val Val Ala Lys Met Glin Val Met Val Asn Arg Tyr Pro 
195 2OO 2O5 
Thir Trp Gly Asp Thr Val Glu Val Asn. Thir Trp Val Asp Llys Lieu. Gly 
21 O 215 22O 
Lys Asn Gly Met Arg Arg Asp Trp Lieu. Ile Ser Asp Cys Asn Thr Gly 
225 23 O 235 24 O 
Glu Ile Lieu. Thr Arg Ala Ser Ser Val Trp Val Met Met Asn Glin Lys 
245 250 255 
Thir Arg Arg Lieu. Ser Lys Ile Pro Asp Glu Val Arg Arg Glu Ile Glu 
26 O 265 27 O 
Pro His Phe Val Asp Ser Pro Pro Val Ile Glu Asp Asp Asp Arg Llys 
27s 28O 285 
Lieu Pro Llys Lieu. Asp Asp Llys Thr Ala Asp Ser Ile Arg Lys Gly Lieu. 
29 O 295 3 OO 
Thr Pro Llys Trp Asn Asp Lieu. Asp Val Asn Gln His Val Asn. Asn. Wall 
3. OS 310 315 32O 
Lys Tyr Ile Gly Trp Ile Lieu. Glu Ser Thr Pro Glin Glu Ile Leu Glu 
3.25 330 335 
Thr Glin Glu Lieu. Cys Ser Lieu. Thir Lieu. Glu Tyr Arg Arg Glu. Cys Gly 
34 O 345 35. O 
Arg Glu Ser Val Lieu. Glu Ser Lieu. Ser Ala Ala Asp Pro Ser Gly Lys 
355 360 365 
Gly Phe Gly Ser Glin Phe Gln His Lieu. Lieu. Arg Lieu. Glu Asp Gly Gly 
37 O 375 38O 
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Glu Ile Val Lys Gly Arg Thr Glu Trp Arg Pro Llys Thr Ala Gly Ile 
385 390 395 
Asn Gly Ala Ile Pro Ser Gly Glu Thir Ser Pro Gly Asp Ser 
4 OS 41O 
What is claimed is: 
1. A method of producing triacylglycerols (TAGs) com 
prising medium-chain fatty acids (MCFAS) in an organism, 
comprising: 
introducing a transgene into the organism, wherein the 
transgene comprises at least one nucleic acid sequence 
encoding an acyltransferase, wherein the at least one 
acyltransferase exhibits a Substrate specificity for Satu 
rated fatty acids; 
thereby producing TAGs comprising MCFAS in the organ 
1S. 
2. The method of claim 1, wherein at least 20% of the TAGs 
comprising MCFAs have a C8:0 or a C10:0 at sn-2 position. 
3. The method of claim 1, wherein the saturated fatty acids 
are selected from the group consisting of C8:0 and C10:0. 
4. The method of claim 1, wherein the at least one acyl 
transferase is a lysophosphatidic acid acyltransferase (LPAT) 
or a diacylglycerol acyltransferase (DGAT). 
5. The method of claim 1, wherein the at least one acyl 
transferase is a lysophosphatidic acid acyltransferase (LPAT) 
and a diacylglycerol acyltransferase (DGAT). 
6. The method of claim 4, wherein the nucleic acid 
sequence encoding the LPAT is selected from the group con 
sisting of a sequence having at least 95% sequence identity to 
SEQID NO:1 and a sequence having at least 95% sequence 
identity to SEQID NO:3. 
7. The method of claim 4, wherein the nucleic acid 
sequence encoding the DGAT is selected from the group 
consisting of a sequence having at least 95% sequence iden 
tity to SEQ ID NO:7 and a sequence having at least 95% 
sequence identity to SEQID NO:9. 
8. The method of claim 1, wherein the nucleic acid 
sequence encoding the at least one acyltransferase is selected 
from the group consisting of a nucleic acid sequence having at 
least 95% sequence identity to SEQID NO:1, a nucleic acid 
sequence having at least 95% sequence identity to SEQ ID 
NO:3, a nucleic acid sequence having at least 95% sequence 
identity to SEQID NO:7, and a nucleic acid sequence having 
at least 95% sequence identity to SEQID NO:9. 
9. The method of claim 1, wherein the organism further 
comprises a nucleic acid sequence encoding a medium-chain 
fatty acid (MCFA)-specific thioesterase FatB. 
10. The method of claim 9, wherein the nucleic acid 
sequence encoding the MCFA-specific thioesterase FatB is 
selected from the group consisting of a nucleic acid sequence 
4 OO 
having at least 95% sequence identity to SEQ ID NO:11, a 
nucleic acid sequence having at least 95% sequence identity 
to SEQID NO:13, and a nucleic acid sequence having at least 
95% sequence identity to SEQID NO:15. 
11. The method of claim 1, wherein the organism is 
selected from the group consisting of a plant and a microbe. 
12. The method of claim 11, wherein the plant is Camelina 
Sativa. 
13. The method of claim 1, wherein the transgene com 
prises a promoter. 
14. The method of claim 13, wherein the promoter is a 
seed-specific promoter. 
15. The method of claim 11, wherein the at least one 
nucleic acid sequence encoding an acyltransferase is oper 
ably linked to a seed-specific promoter. 
16. The method of claim 15, wherein the medium-chain 
fatty acids are produced in the seed. 
17. The method of claim 1, wherein the introducing step is 
performed using Agrobacterium transformation, particle 
bombardment, or electroporation of protoplasts. 
18. A method of producing triacylglycerols (TAGs) com 
prising medium-chain fatty acids (MCFAS), comprising: 
providing an organism comprising a transgene, wherein 
the transgene comprises at least one nucleic acid 
sequence encoding an acyltransferase, wherein the at 
least one acyltransferase exhibits a Substrate specificity 
for saturated fatty acids; 
growing the organism under appropriate conditions; and 
obtaining TAGs comprising MCGAS from the organism. 
19. The method of claim 17, wherein the TAGs are used in 
biofuel, jet fuel, detergents, and chemical feedstocks. 
20. A method of increasing the amount of triacylglycerols 
(TAGs) comprising medium-chain fatty acids (MCFAs) in the 
seed oil of a plant, comprising: 
providing a plant comprising a nucleic acid encoding a 
FatB polypeptide; 
introducing a heterologous nucleic acid molecule into the 
plant comprising at least one nucleic acid sequence 
encoding an acyltransferase, wherein the at least one 
acyltransferase exhibits a Substrate specificity for Satu 
rated fatty acids, 
thereby increasing the amount of TAGs comprising 
MCFAs in the seed oil of the plant without significantly 
changing the total oil content in the seed. 
k k k k k 
